Analysis of chemotherapy screening assays using MCMC methods by Hollyer, Justine
        
University of Bath
PHD








Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. May. 2019
A nalysis of Chem otherapy  








C O PY R IG H T
Attention is drawn to the fact th a t copyright of this thesis rests with its author. 
This copy of the thesis has been supplied on the condition th a t anyone who 
consults it is understood to recognise th a t its copyright rests with its author and 
th a t no quotation from the thesis and no information derived from it may be 
published without the prior w ritten consent of the author.
This thesis may be made available for consultation within the University Library 
and may be photocopied or lent to other libraries for the purposes of consultation.




INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U601795
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
j^ r • ”v«; w -jv '->■ T - ’X^U*”'
U . : ,TH 1
-  5  j a m  ?< ^ l  . I
t i j i
■i • tw un> w im m ivn \ "*v \r ■ m m  imftUWWl
Abstract
Aim s
Chemotherapy screening assays are used to  try  and identify which drugs induce 
a response in patients ex vivo in the hope th a t it will correlate well with an in 
vivo response. This thesis is primarily concerned with identifying the dose at 
which 90% kill rate  is achieved (the LC90) and comparing these results to get an 
indication of which patients are likely to respond to which drugs.
D ata
The finalised da ta  set consisted of over 40,000 assay results on 42 different drugs. 
Each patient had several assays performed on a number of these drugs. The 
number of drugs tested varied across patients depending on drug availability and 
previous treatm ent history.
Assay M ethods
Slides are prepared with 5 “spots” of untreated cells. Control slides are left 
untreated to  provide a baseline count whilst the other slides are treated  w ith 5 
decreasing dose levels for each drug tested. Cell survival is noted at each dose and 
recorded in categories which represent overlapping proportions of cell survival.
Statistical A nalysis
We develop a model using all the prior information we have. The Metropolis- 
Hastings algorithm is used to construct a Markov Chain and an analysis run 
for each drug. From these analyses we note the posterior distributions for all 
variables and report estimates of the slope and location of the dose response 
curve as well as the LC90s.
We use the information gained about the posterior distributions of our variables 
in order to  develop a further model to  analyse extra cases without re-running the 
whole analysis.
Lastly we consider the problem of outliers and we look a t methods to identify 
them  and assess their influence.
R esults
The resulting LC90s have great variation both between drugs and within drugs.
The accuracy of the estimate depends greatly on the quality of data. Small 
control values and missing data  contribute to poor estimates.
An efficient procedure can be derived for looking a t additional assays using the 
information gained from the initial main analyses.
The presence of outlying observations does not have a large effect on resulting 
estimates.
Convergence diagnostics often give conflicting results on burn-in, run length 
required and convergence depending on the technique employed.
Conclusions
We are confident th a t with sufficient da ta  our estimates are reliable. In those cases 
where there is only a small number of cells to assess, these should be counted 
accurately rather than  categorised into overlapping and often very wide bands. 
This will also reduce possible outliers.
We note th a t commonly used convergence diagnostics cannot wholly be relied 
upon. Work is currently active in this area.
The clinical implications from these results mean patients can have non invasive 
tests rapidly performed on a variety of drugs in order to  obtain the best possible 
treatm ent. Drug induced resistance can be minimised by using these indicated 
drugs. O ther benefits include cost and reduced side effects if more than  one drug 
is shown to produce equal efficacy ex vivo.
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The initial aim of this thesis is to  develop a procedure which will utilise a data  
set of assay results obtained from patients with chronic lymphocytic leukaemia 
and hence produce accurate estimates of the effective dose required for treatm ent. 
The assays used are concerned with ascertaining the proportions of cancerous cells 
killed by adding different drugs to tum our samples a t various concentrations.
1.1 Background
Information has been collected over a number of years by the B ath Cancer 
Research Unit to  test the efficacy of a wide variety of drugs on tum our and blood 
samples received for analysis. Even though suffering from seemingly identical 
diseases, individuals respond very differently to different drugs making this a 
particularly difficult illness to treat. One consequence of failing to  identify 
an effective treatm ent initially is a drug induced resistance which decreases 
the therapeutic effect of further drug regimes making subsequent treatm ent 
increasingly more difficult. It is known th a t patients who dem onstrate sensitivity 
to  particular drugs ex vivo will also often respond well in vivo and hence any 
potentially effective drugs indicated can be used in treatm ent. Ex vivo is used 
to denote work with fresh cells as opposed to cell lines in vitro. The objective 
of the assay therefore is to  determine how likely it is th a t a patient will respond
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to a particular drug by noting th a t the results obtained ex vivo correlate well 
with actual responses (Bosanquet, 1991 and 1995). Also, if previous standard  
therapies have already been shown to have failed, the assays can often identify 
drugs which may not have been previously considered and these will include 
“unusual” non-standard treatm ents.
The assay in use has been refined so it now has the ability to  test a wide variety 
of drugs quickly and easily so results can be obtained with minimum delay. A 
patient is said to  be sensitive to a drug if the dose a t which a t least 90% of 
cancerous cells are killed in the assay is low when compared to the results from 
other patients with the same disease. This does not necessarily imply an effective 
treatm ent however, merely th a t a patient has shown a better response when 
compared to results from other patients. Since many of these drugs are highly 
toxic with undesirable side effects, even seemingly low doses may not be tolerated.
The d a ta  set under investigation is large with over 40,000 records and is 
structurally complicated w ith many missing observations. Each record varies 
both in the amount of information held and its quality.
Every patient has had several assays performed from a selection of 40 drugs. 
Assays are duplicated to  test for repeatability and also to provide a  back-up 
measure in case of assay failure. The results may be recorded twice by different 
scientists to  ensure agreement.
Owing to the structure of this da ta  set and the need to  estim ate unobserved 
variables, Markov Chain Monte Carlo (MCMC) m ethods have been used since 
they offer a framework in which to simulate the actual processes involved in 
obtaining the da ta  and hence produce estimates of unobserved variables where 
the main interest lies.
MCMC methods have become an increasingly common way in which to analyse 
da ta  where more traditional methods are unable to  cope with model complexity 
and intricate da ta  structures. W ith ever developing computing power, such 
com putational methods have become increasingly accessible on even small 
platforms. W hilst existing packages have been w ritten utilising MCMC methods, 
they are limited in their use owing to their inability to  analyse more complicated
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models satisfactorily. Hence a program has been specially w ritten as part of this 
project to cope with the data  structures arising and provide estimates of the 
variables of interest.
The first part of this thesis is concerned with identifying a model which mimics 
the data  collection procedure. This initially entailed developing the model using 
simulated data  which had simpler structure than  the final d a ta  set in use. The 
final da ta  set proved to be far more complex than  originally envisaged and meant 
extending the original model. Even using the simplified da ta  set, its structure 
meant it was impossible to use standard analyses and packages satisfactorily. 
Since the results were recorded with varying amounts of accuracy, this also has 
to be accounted for. The missing da ta  variables were simulated by running a 
Markov chain. Since non-standard distributions had to be used, a Metropolis- 
Hastings Algorithm was the basis for performing updates on the simulations.
Further aims of this project include the assessment of outliers in the data  and 
their effect in the analyses. Also of importance is the ability to analyse new cases 
separately, w ithout the need to run a full simulation each time. This is done 
by taking information from previous runs about the posterior distributions of 
the salient variables in order to provide information about each particular drugs’ 
behaviour.
1.2 Structure of the thesis 
Chapter 2: M edical Background
The next chapter is concerned with explaining the medical background and 
techniques employed to perform the assay and ensure results are as accurate 
as possible.
This chapter also demonstrates the usefulness in utilising these assay results. 
Those patients whose treatm ent is based on those drugs shown to be effective ex 
vivo have a considerably better prognosis than  those who show no sensitivity to 
any of the drugs. It is hoped th a t by using the indicated drugs, survival times
3
of patients showing some sensitivity will improve even if treated  with different 
drugs than  those shown to have the best ex vivo results.
Chapter 3: Bayesian Analysis using M CM C
This chapter gives a brief introduction to Bayesian methods and the underlying 
theory. It deals with the two most popular methods of implementation of Markov 
Chain Monte Carlo and surrounding issues.
Chapter 4: M odel Specification
We describe the model in use and the stages in its development. The initial data  
set used to test the initial model was simulated to be a smaller and simplified 
version of the one in final use. As the structural complexities of the final 
da ta  set were introduced, the model evolved to  cope with these features. The 
choice of prior distributions for the variables specified in the model was based 
on information gathered from the scientists. These were chosen to include all 
possible values which may arise so whilst they were not non-informative, they 
were sufficiently diffuse to cope with all potential values which were thought to 
be possible within the data.
Chapter 5: M odel Im plem entation
Here we discuss the choice of algorithms used to implement the model described 
in C hapter 4. This breaks down into four m ajor procedures: reading in of da ta  
into suitable da ta  structures, initialisation of all the variables to  be updated, the 
updating of these values whilst running the Markov chain and finally the output 
of the results. We take particular care with specifying the acceptance probability 
calculations since they are vital in obtaining suitable posterior distributions.
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Chapter 6: M odel Validation
In order to satisfy ourselves th a t the results from the model are reliable we 
perform validation checks on the output. These consist mainly of convergence 
diagnostics which have been implemented in a public package called CODA. This 
chapter looks a t the results of various techniques and compares the diagnostics 
of the different methods.
Chapter 7: Results
Although we are primarily interested in the estimates of the LC90s and how 
reliable they are, we are also interested in the resulting cell survival curves and 
the associated parameters. We look at the variation between drugs, between 
patients within a particular drug and also how the different assays compare for 
the same patient. We also consider the problem of examining an additional 
patient after the main analysis has been carried out.
Chapter 8: Outliers
This chapter is concerned with the effect of potential outliers. It looks a t ways 
of identifying them  and various theories about their treatm ent. We deal with 
them  by om itting the suspect values and treating them  as though they were 
missing. The resulting posterior distributions for the observations in question 
are compared with the om itted values in order to compare their discordancy 
and also to  assess the possible influence on the estim ated LC90 and cell survival 
curves.
Chapter 9: Conclusions
Finally we present a review of the results obtained and the methods used in 
their analysis. We look a t possible recommendations for implementing new data  




The aim of cancer therapy is to  kill tum our cells and /o r prevent division of cancer 
cells and hence arrest the disease. There is good evidence to  indicate th a t assays 
performed on patient cell samples which measure either in vitro or ex vivo the 
kill rate  of cells or the inhibition of cell proliferation may be indicative of clinical 
response. (In vitro refers to  cell lines and ex vivo denotes work with fresh cells 
whereas the term  in vivo refers directly to the patient). In  vitro drug sensitivity 
assays have been used for over 40 years as a way to  identify potential in vivo 
sensitivity of individual patients to specific anti-cancer chemotherapy (Bosanquet 
1994). In  vivo denotes the actual patient response. Even patients with seemingly 
identical diseases can respond very differently to  the same drug, which makes it 
very hard to prescribe effective treatm ent prospectively. Hence, many in vitro 
drug sensitivity tests have been developed with much work being concentrated 
on short-term  assays and their predictive accuracy, i.e. the agreement between 
test result and actual patient response. Bosanquet (1991) dem onstrated th a t 
patients with a low tum our cell survival in vitro (i.e.,less than  the median) have 
an improved response ra te  in vivo when compared to  the overall response. This 




Older assays used in the 1970s took 2 to  3 weeks to  perform and were labour 
intensive, consequently their use was limited. Since then, many shorter term  tests 
taking less than  a week have been developed, making them  far more convenient to 
use. One such assay is the Differential Staining Cytoxicity assay (DiSC) originally 
devised by Weisenthal (Weisenthal, Marsden, et al. (1983), Weisenthal, Dill, et 
al. (1983)) taking around 4 days. This DiSC assay has been further developed 
to  make it particularly well suited to  the testing of large numbers of drugs using 
relatively small tum our samples (Bird et al. 1988). It has therefore been the 
m ethod used to test all the samples examined in this study.
At the B ath Cancer Research Unit in the Royal United Hospital, Bath, samples of 
both solid tum ours and leukaemias are analysed in an effort to  identify the drugs 
which are most likely to  produce a response in the patient. This information 
can then be referred back to the physician who is thus empowered to  make an 
informed choice about the treatm ent of a patient by selecting a regime from those 
drugs shown to be effective.
2.1.1 Benefits
A part from the obvious need to find a cure or arrest the spread of disease, 
identifying the best potential treatm ent regime indicated from these assays has 
further implications. There are many drugs available and patient response 
differs widely to each treatm ent. Such testing enables an informed choice of 
chemotherapy to be made on the basis of a response ex vivo. Patients experience 
drug induced resistance: the more courses of chemotherapy received, the less 
likely the patient is to respond to further courses. If an ineffective treatm ent is 
given initially, it will reduce the beneficial effect of a more efficacious treatm ent 
given later on. Hence the therapeutic benefit of a potentially effective treatm ent 
is reduced if previous courses have already been administered. Combinations of 
some drugs, especially those which work similarly, have high drug cross-resistance 
patterns to a response ex vivo (Bosanquet 1991).
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Also, many of these drug have high toxicities with unpleasant side-effects. So, if 
two drugs give similar results ex vivo but one is known to  have less severe side 
effects this could be given in preference. Similarly w ith cost, some treatm ents, 
especially those which are platinum based, can be extremely expensive so patients 
could be given a cheaper drug w ithout detriment.
The DiSC assay thus enables many drugs to be tested simultaneously on tum our 
samples, enabling the physician to identify potentially effective treatm ents which 
may not have been otherwise considered. This is especially helpful if previous 
courses of standard treatm ent have already failed. If used beforehand the assays 
may in fact have shown th a t these standard drugs are likely to  have little beneficial 
effect so they can be avoided altogether.
2.1.2 Clinical correlations
In order for the assay results to be reliable guides for treatm ent choice, ex vivo 
results should agree well with in vivo results. A clinical correlation is obtained 
by categorising both the ex vivo and in vivo responses into either sensitive or 
resistant cases and then comparing the agreement of these variables. A patient 
response is defined as either a complete or partial response. However, an assay 
response is not so easily dichotomised since results cover a  broad range from very 
sensitive to very resistant. Picking a cut-off point can only be done satisfactorily 
with reference to the clinical data.
2.2 Assay m ethods
For each patient, a number of slides each with five “spots” of the sample tum our 
are prepared. (Figure 2 - 1 ).
Two control slides are left untreated in order to obtain a “baseline” count for 
the number of cells examined. Up to  40 further slides are treated  with different 
drugs. Each slide is treated with a single drug. The drugs themselves are each 
diluted four times by a constant factor to  give five different concentrations. The
Figure 2 - 1 : Diagrammatic representation of treated slide. Spot “A ” is treated with 
the maximum concentration (MC), Spot “B ” is treated with M C /D F, where DF=  
the dilution factor, ((C ”, “D ” and “E ” are treated with M C /D F 2, M C /D F 3 and 
M C / D F A respectively.
dilution factor used depends on prior knowledge of the ex vivo performance of 
th a t particular drug and will hopefully span the cell survival ra te  of interest. 
Even for the same drug, different dilution factors may be used as knowledge of 
a particular drug’s behaviour is gained. The drugs are incubated w ith cells for 4 
days in a controlled environment. A known number of duck blood cells are added 
as a control measure: the number of tum our cells is not known in advance. The 
cells are then stained and then centrifuged onto collagen coated slides. The slides 
are fixed and counterstained before examination. Duplicate back up slides are 
also made as a precaution against failure or contam ination. These duplicates are 
sometimes used as an additional measure to ensure consistency.
Up to two scientists are employed in counting the baseline number of cells and 
hence ascertaining the proportion of cells killed. So for each patient there is a 
maximum of four sets of results for each drug tested. The control and treated 
slides are stored in the same box and analysed together.
2.2.1 Control measures
One of the problems during preparation of these slides comes when they are 
centrifuged: it is not unknown for cells to  “disappear” . In order to assess any cell 
loss, a known quantity of duck cells are added. If all the duck cells are still present 
after the centrifusion then it can be safely assumed th a t none of the patients cells 
have been lost either and the slide is reliable. The different types of cells are easily 
distinguishable when examined under a microscope: after staining, the duck cells 
appear as large blue “blobs” whereas the patient cells are far smaller and range
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in colour from bright magenta for live cells to nearly black for dead and dying 
ones. Thus it is relatively straightforward to differentiate the live and dead cells 
from the duck cells and ascertain the reliability of the slide. If a slide is seen to 
have failed, the backup slides are used instead.
Cross contam ination can also occur with some drugs during incubation. Certain 
drugs not only react with the the cells to which they have been added, but also 
to  others in the same box leading to  higher kill rates than  would occur normally. 
Care is taken to ensure these drugs are stored and incubated separately.
2.2.2 Counting m ethods
In order to get a control value, i.e., the expected num ber of live untreated cells for 
each patient per square, the cells are counted using a microscope w ith a 1 0  x 1 0  
grid of squares in the eyepiece. The lens is positioned over a “representative” 
area of each spot in tu rn  on the first control slide. The number of cells in one 
grid square are counted manually and the value noted. Owing to  the irregular 
distribution of the cells, 1 0  such squares are chosen to  be counted and then 
averaged to  give a baseline count.
The second control slide is counted in the same m anner bu t unless the resultant 
baseline value differs from the first (by more than  30%), only the first value is 
recorded.
The number of treated cells is ascertained in a similar m anner bu t the absolute 
value of remaining cells is not noted, instead a num ber of overlapping categories 
is used to record this information. These categories are very narrow where there 
is a low survival rate, since this is of most interest, and conversely, where the 
survival rate is high, the categories have considerable overlap and are relatively 
wide. The reason for recording da ta  in this m anner is the considerable reduction 
in time spent counting individual cells where accuracy is not imperative. E xtra 
care is taken where survival rates are low and actual counts are made, otherwise 
the proportion surviving relative to the control value is estim ated. Owing to  the 
random  distribution of cells it is possible to obtain estim ated kill rates which are 






1) 0 0 - 2 %
2) 5 0 . 1  - 8 %
3) 1 0 2 - 1 2 %
4) 15 10- 25%
5) 30 15- 45%
6) 45 30- 60%
7) 60 45 -100%
8) 1 0 0 > 60%
Table 2.1: Initial categories used to denote proportion o f surviving cells
of the control slide. This is more likely when there is only a small quantity of 
control cells.
Since the first recording of results, more categories have been introduced to  make 
the recording of d a ta  more accurate and the ones in use a t present are shown in 
Table 2.1
2.2.3 LC90
The quantity of interest is the Lethal Count 90 (LC90): th a t is the drug 
concentration a t which 90% of cells are killed. Since only 5 drug concentrations 
are used this was initially estim ated as the weakest concentration a t which less 
than  1 0 % cells survive. If the sample was very resistant, the LC90 would often 
not be achieved at the concentrations tested. The converse problem could also 
happen when the sample is very sensitive and even the lowest dose would kill all 
cells.
The maximum concentration and dilution factors were chosen to  try  and span 
the LC90 but, given the vast range of responses, this was not always possible. As 
further information was gained about particular drug behaviour, the dose levels 
were changed to  reflect this additional knowledge.
















LC90 40 2 3
Log,0 (Dose)
Figure 2-2: Estimation of the LC90.The vertical bars represent the estimated 
range of surviving cells. The solid line denotes the curve fitted to the mid-point 
of these ranges. The dotted line touches the curve at the point where 90% of cells 
are estimated to be dead and the relevant concentration (LC90) is read from the 
x-axis.
error and part of the aim of this project is to give more accurate estimates. The 
LC90 has previously been ascertained by graphing the midpoint of the interval 
of the cells surviving, fitting a curve to these 5 sets of points and then reading 
off from the axis the drug concentration corresponding to 10% survival (Figure 
2-2).
2.2.4 Sensitivity
A patient is said to be sensitive to the drug ex vivo if the LC90 is achieved at a 
low dose when compared to other patients with the same disease. However this is 
subject to misinterpretation. A patient may have a good result when compared to 
other patients but the drug may, in general, be very poor at killing the cancerous 
cells. So a “good” assay result does not necessarily mean the patient will respond 
well in vivo and this has to be taken into consideration when reporting the results 
back to the doctors.
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2.3  S u rviva l an a ly ses
It has been shown that response rates and length of survival can be considerably 
enhanced utilising the results from these assays. Even allowing for known 
effects such as stage of disease, age and number of previous courses, the patient 
sensitivity to drugs tested ex vivo, whether exploited or not, is also an important 
independent factor in the patient’s response and overall survival. A subset of data 
with further information regarding survival times and extra prognostic factors was 
analysed. The resulting Kaplan-Meier curves can be seen in Figure 2-3 and they 












Figure 2-3: Kaplan-Meier Curves stratified by ex vivo sensitivity. The resistant 
group (bottom curve) have the worst estimated median survival at 1.0 years, 
the unexploited and exploited groups have median survival of 1.5 and J^ .2 years 
respectively.
Those patients whose treatment includes any of the drugs shown to be effective 
ex vivo from the assays (the exploited sensitivity group) have the best survival 
rates whereas those shown not to be sensitive have, predictably, the worst. The 
intermediate group are those patients who have been shown to have a response
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ex vivo to a t least one of the drugs tested but for various reasons none of the 
indicated drugs have been used in the treatm ent prescribed. This unexploited 
sensitivity group, if treated using those drugs to  which the patient is likely to 
be sensitive, are likely to have a survival curve approaching th a t of the exploited 
sensitivity group.
It should be noted th a t the data  on which this particular analysis is made 
are observational rather than  from a randomised clinical trial. However, the 
differences in survival between these groups are very marked and extremely 
unlikely to be due to chance or any possible bias.
Thus there is compelling evidence th a t assay-based treatm ent does lead to  better 
survival and remission rates than  those observed for patients with unexploited 
sensitivity. Both these groups out perform the assay-resistant patients for whom 
the only realistic treatm ent is palliative or investigational.
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Chapter 3 
Bayesian Analysis using M CM C
MCMC methods provide a framework which enables complex statistical modelling 
to be carried out via simulations. Traditional m ethods could require either 
a simplification of the problem in order to utilise existing methods or new 
methodologies which may have to be developed.
3.1 An introduction to  Bayesian analysis
We shall use the principles of Bayesian d a ta  analysis to  build models and 
summarise unobserved quantities of interest. In order to  make inferences on 
variables we cannot examine we use information from d a ta  which we can 
observe. This is done by obtaining a posterior distribution for the variable 
of interest. A full probability model is specified in which all observable and 
unobservable quantities are treated as random variables, each with associated 
prior distributions. Bayesian modelling does not distinguish between observables 
and param eters of a statistical model: they are all considered to  be random 
quantities with individual distributions. The prior probability distribution must 
be consistent with knowledge about the underlying problem and the likelihood 
with d a ta  collection processes, for example whether the d a ta  are discrete, or 
subject to a restricted range.
The joint distribution can be specified over all random quantities, which comprise
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two parts: a prior d istribution P(9) and a likelihood P(D\9)  where 9 denotes the 
model param eters and D  the data  observed.
The joint probability model can then be specified in term s of the prior distribution 
and the likelihood,
P (D ,9 )  = P(D\9)P(9). (3.1)
Bayes theorem is used to obtain the posterior distribution of 9 conditional on the 
da ta  D,
P m )  =  M
where P (D ) = f  P{9)P{D\9)d9.
Since P{D )  does not depend upon 9, it may be om itted yielding the unnormalised 
posterior density:
P(9\D)  oc P{9)P(D\9). (3.3)
Bayes Rule means th a t the data  D  affect the posterior inference only through 
P(D\9) - the likelihood function. In this way, Bayesian inference obeys the 
likelihood principle, which states th a t for a given sample of data, any two 
probability models P(D\9)  th a t have the same likelihood function yield the same 
inference for 9 (Gelman et al. 1995). Bayesian methods enable statem ents to 
be made about the partial knowledge available, based on data, concerning some 
situation (unobservable or as yet unobserved) in a systematic way in agreement 
with probability theory. The guiding principle here is th a t the state  of knowledge 
about anything unknown is described by a probability distribution.
Thus the task is to  specify the full model P (9 ,D )  and compute summaries for 
P(9\D).  W ith MCMC methods this is achieved by sampling from a Markov chain 
which has been constructed to have the correct limiting distribution. Inferences 
can then be made from summaries which can be obtained from these samples.
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3.2 Markov Chain M onte Carlo sam pling
Suppose we wish to  calculate E[ f ( X) ]  for a specified function /  when X  follows 
the distribution 7r. If it were possible to draw independent samples { X i \ i  =  
1, from the desired distribution 7r(x) we could approxim ate E[ f ( X) ]  by the 
sample mean
i  £ /(* « )•  (3-4)n  • 1 t=i
However, if 7r is a complex distribution, it may be infeasible to  obtain such samples 
directly.
The idea in MCMC sampling is to create a Markov Chain w ith limiting 
distribution equal to  7r, the distribution of interest, and trea t samples obtained 
after the Markov chain has run for a long time as realisations from this 
distribution. For an aperiodic Markov chain, the stationary distribution is also 
the limiting distribution. If {X i : i =  1 ,2 ,...}  form a Markov chain, X i+1 depends 
on Xo, .. . ,X i  only through X i  and under certain conditions the chain gradually 
“forgets” its initial state  and the distribution of X n converges to  the limiting 
distribution as n  —>• 0 0 .
In order to  construct such a chain we need to  carry out the following procedures
•  Set up a chain with a limiting distribution of 7r.
•  Discard the burn-in, the initial m  samples.
•  E[ f ( X) ]  can then be estim ated by
1 n^  E /(*>■n — m  .
1=771+1
After a sufficiently long initial burn-in period of m  iterations, X m+i, . . . ,X n will 
be dependent samples from the stationary distribution 7r(.). Realisations from 
such a chain are necessarily correlated but the {Aj} do not necessarily need to 
be independent in order to be useful.
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There are, however, certain conditions th a t the Markov chain must satisfy in 
order for it to produce reliable samples (Tierney, 1995).
•  Irreducibility: The chain must be able to reach all parts of the state  space 
from any other part of the state  space.
•  Recurrence: This is the property th a t all parts of the the chain will be 
reached infinitely often, a t least from almost all starting points.
•  Convergence: The chain must first achieve convergence to  a stationary 
distribution in order for samples to have the required posterior distributions. 
There are numerous methods by which to assess convergence which are 
discussed in further detail later.
The X{ are generated such th a t X{+\ depends only on X{. Hence it depends 
only on X q through the intervening variables (X i, X<i, ..., X i_i). Thus the 
chain gradually forgets its initial state  and will eventually converge to  a unique 
stationary distribution.
Convergence to the required distribution is ensured by the ergodic theorem which
where 7r =  (7Ti,..., 7rn) is the unique solution to irP =  7r, (if 7r is a discrete 
distribution).
Burn in samples are discarded giving the param eter estim ator as the ergodic 
average:
states
P ( X k+N =  j \ X k — i) -> nj as N  0 0 (3.5)
(3.6)
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3.3 Two im plementations of MCMC
3.3.1 The M etropolis-H astings Algorithm
Hastings (1970) further developed the sampling m ethod introduced by Metropolis
et al. (1953) into a more generalised form. In order to  obtain these samples, the 
Metropolis-Hastings Algorithm is thus used to construct a Markov Chain with 
its stationary distribution equivalent to the one of interest.
To construct such a chain the algorithm consists of the following steps:
1. Initialize Xo = xq
2. At time i, when X i - 1 =  Xi-i, for Xi, generate proposal value x'  for Xi.
3. Let Xi  =  x f with probability
otherwise X i  =  Xi-i
4. Repeat from step 2 until desired length of chain achieved after burn-in.
are used any normalising constant cancels, making the calculations considerably 
less complex.
For each state  of X i,  the transition probabilities need to be defined such th a t 
the transition m atrix Q is irreducible: every state  for Xi  can be reached from 
every other state  X j  via intermediate states.
If this transition m atrix is symmetric then the m ethod simplifies to  the Metropolis 
Algorithm.
The proposal distribution g(.|.) can have any form and the stationary distribution 
will be 7r(.). This can be seen by the following argument:
a(xi- i ,x ')  =  min ( 1 (3.7)
From this it can be see th a t t t { x )  does not need to  be fully calculated since as ratios
P (x i+1\xi) =  q{xi+i\xi)a{xi ,xi+l)
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+ I (x i+i = X i )  1 -  /  q{x, \xi)a{x i , x ,i)dx' , (3.8)
where /( .)  denotes the indicator function. The first term  arises from the
acceptance of proposal value x i+\ =  x' and the second from rejection for all
possible values of Xi+\. From 3.7
7r(xi)q(xi+1\xi)a(xi,xi+i) = n(xi+1)q(xi\xi+i)a(x i+uxi).  (3.9)
Using Equations 3.8 and 3.9 for X;+i ^  we then obtain the detailed balance 
equation:
'K{Xi)P{Xi+l\Xi) =  7r(Xi+1)P(Xi \X i+1) (3.10)
Integrating both sides with respect to X i  gives:
J  n{X i)P (X i+1\Xi)dXi = ir(Xi+1). (3.11)
The left hand side gives the marginal distribution of Xi+i under the assumption 
th a t X i  is from 7r(.). Therefore X{+\ is also from 7r(.).
It can be seen th a t a starting value is required for X .  This choice is not crucial 
since owing to the Markov property the chain eventually “forgets” where it started  
and as long as the chain is irreducible, the stationary distribution is not affected. 
However, very extreme values will adversely affect the length of the burn-in period 
and hence the time taken for the chain to  converge.
A cceptance rates
Proposal distributions must be chosen carefully since small steps (Xj+i — X i)  will 
have a high acceptance rate but mix slowly. Conversely, large steps will often 
propose moves to areas of low probability and these will be rarely accepted.
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3.3.2 The Gibbs Sampler
Gibbs sampling (Geman & Geman 1984) is a special case of the Metropolis- 
Hastings algorithm. It is one of the most common ways in which to construct a 
Markov chain since it requires little more than  sampling from the full conditional 
distributions (Gilks et a l  1996).
Conditional distributions are derived from the joint distribution of variables 7r. 
However, unless the prior distributions are conjugate to the likelihood, it may be 
infeasible to calculate the full conditional distributions.
Given a vector of unknowns, u =  (iq, ..., W/c), let denote u with component 
i om itted, i.e. zqq =  (C/1,...,m<_i,w<+i,...,w ^ ). Then with observed da ta  .D, the 
full conditional distribution for component iq is:
(ui\u{i),D).
One implementation of Gibbs Sampling is in the form of the package BUGS 
(Spiegelhalter et al 1994) which constructs a chain using prior distributions and 
conditional relationships as defined by the user. This will be looked a t in fuller 
detail in a later chapter.
3.4 Burn in and convergence
It has been mentioned tha t, when running a Markov chain Monte Carlo, a burn 
in period is required in order for the chain to reach its stationary distribution on 
which our subsequent inferences may be based.
It is impossible to  tell in advance when convergence will been reached and how 
long the burn-in period should be. However, although it is relatively simple to 
see whether a chain hasn’t converged, the converse is unfortunately not true.
Many convergence diagnostics have been developed, some of which have been 
implemented in the package CODA (Best et al, 1995) which will be examined in
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Figure 3-1: Example of simple graph.
more detail in a further chapter.
A simple and informative diagnostic is a plot of the chain. This will show 
whether the chain is mixing well as well as whether convergence may have been 
reached. This is not foolproof however, for example the posterior distribution 
may be multimodal and the chain may be sampling from just one mode with low 
probability of reaching another mode. In this case the chain will need to  be run 
for longer in order for it to  reach all areas of probability, bu t there may be no 
initial indication of this.
3.5 Graphical M odels
If we wish to specify a model for random vector X  w ith a complex multivariate 
distribution, it is useful to  be able to  express any association between the elements 
graphically. A convenient way of expressing such information is to  construct a 
graph.
3.5.1 Graphs
A graph consists of a set of N  nodes and E  edges connecting the nodes. Each 
element of E  is a pair of nodes (A, B ) which denotes an edge between A and B.  
For example, the simple graph in Figure 3-1 show 5 nodes {A, B, C, D, E }  and 4 
edges { ( A ,B ) , ( B ,C ) , ( C ,D ) , ( C ,E ) } .
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3.5.2 Conditional independence
A link between a pair of nodes indicates a relationship between variables and 
confers the status of neighbours between them. The absence of such a link between 
nodes denotes conditional independence given any interm ediate nodes. The graph 
in Figure 3-1 shows the relationship between 5 variables. A  is independent of 
all other nodes given B, written as: A  _LL C ,D ,E \B ,  where _LL denotes the 
independence operator. In the same way B is independent of D and E given C, 
denoted by: B 1 ± D , E\C. In general, a node is independent of all other nodes 
given its immediate neighbours.
3.5.3 D irected graphs
In a directed graph, each edge {A, B }  is an ordered pair with a connection from 
A  to B.  We refer to  the antecedents of a node as offspring. Each offspring will 
have a set of parents unless they are founder nodes with no parents.
Introducing directed links introduces the concept of ordering of the nodes. For a 
set of nodes K  =  {1,2,...&} such th a t for all i and j  in this set, either i < j  or 
j  < i. We can then write 1 -< 2 A;. In a directed graph, such ordering
means th a t any edge can have only one possible direction.
3.5.4 D irected acyclic graphs
Extending graphs to  include directed edges yields the problem of cycles. Initially 
this may at first seem desirable in th a t it would appear to have possibilities of 
modelling “feedback” . Unfortunately there is no suitable joint probability to 
model such a situation, hence graphs used to model conditional dependence are 
not perm itted to  contain directed cycles.
It turns out th a t restricting the directed graph to  exclude directed cycles, 
yielding a directed acyclic graph (DAG), is equivalent to  supposing the nodes 
are completely ordered (W hittaker 1989).
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Figure 3-2: Example of a directed acyclic graph (DAG) showing a Pedigree.
Figure 3-2 shows a naturally occurring example of such a graph stemming from 
genetics and depicts a pedigree in which there are founders, parents and offspring. 
Nodes {1,2,..., 7} are the founders, nodes {8,..., 12} are the offspring of the 
founders etc. W hilst the nodes in this graph are necessarily compelled to have 
two parents owing to its da ta  structure, this is not a general constraint and nodes 
may have any number of parents.
3.5.5 Graphical models
A graphical model is a probability model for multivariate random  observations 
whose independence structure is characterised by a graph. It consists of a family 
of probability density functions th a t incorporates a specific set of conditional 
independence constraints listed in a DAG. As such it is a useful tool to  represent 
the relationships between variables in our model and offers a convenient way to 
encode this information.
We use DAGs to graphically represent the model we wish to  implement. Here the 
nodes represent the variables and the relationships/dependencies between them 
are denoted by the links.
The conditional independence assumption means th a t the full joint distribution 
of all quantities has a simple factorisation in terms of the conditional distribution 
of each node given its parents: this is easily determined from the DAG. Hence 
only the parent-child distributions are required in order to fully specify the model.
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W ith Bayesian models, the joint distribution of the data  and param eters is a 
product of many terms, each involving only a subset of the parameters. Thus 
a DAG is a convenient and simple way of expressing the complex conditional 
inter-dependencies which may exist between variables.
The joint distribution can be specified as a product of all terms. For any node k, 
denoting the remaining nodes by Ar\{/c}, the full distribution is thus:
f l ,2, . . .k =  f k \ K \ { k } f { k - l ) \ K \ { k t{ k - l ) } f ( k - 2 ) \ K \ { k t( k - l ) , ( k - 2 ) } — f 2 \ l f l ’ (3.12)
In order to obtain the full conditional distribution for node A;, we have
P ( k \K \k )  oc p(k, K \ k )  (3.13)
oc terms in p{K)  containing k
= p(k\ parents [A;]) p(l\ parents]/]).
k € parents[z]
Hence the conditional distributions for each k  depends on the values of its parents, 
offspring and the offsprings’ other co-parents, greatly reducing the number of 
term s involved.
We therefore use DAGs as a way of expressing the graphical model for our 
problem. We use the conditional independence assumptions to  reduce the 
complexity of the model since many components have a simple factorisation given 
its parents. Each node represents a variable in out problem. This may be directly 
observed e.g. the control value or a stochastic node, i.e. one we wish to  simulate 




4.1 Description of data
In order to  develop an adequate model for the problem, it is essential to describe 
the mechanism by which the data  arise. This involves modelling the process 
by which the d a ta  are collected which includes both  recorded data, as well as 
unobserved or unrecorded “hidden” variables.
The initial da ta  set was a smaller simplified version of the one in final use. This 
d a ta  set did not allow for more than  one control value or more than  one replicate 
of the assay d a ta  categories. It was also assumed th a t maximum concentrations 
and dilution factors were kept constant for each drug (as the recording of the 
assays became more sophisticated and more knowledge was gained, these were 
often changed). It was considered sufficient to  include just five categories in which 
to  record the number of surviving cells.
We discussed the interpretation of these categories with Dr Bosanquet and 
concluded th a t they corresponded to the ranges of cell survival shown in Table 4.1. 
Here, proportions are relative to the number of cells recorded for the control slide.
The information recorded for patient i is as follows:






1) 0 0-5 .5%
2) 10 4.5- 12%
3) 30 10- 50%
4) 60 40- 85%
5) 100 >  70%
Table 4.1: Final categories used to denote proportion of surviving cells.
2. Xj where j  =  1 , 5 .  The dose levels: this is calculated from the maximum 
concentration used, (c), and the dilution factor, (d).
3. Yij where j  =  1, ...,5. The category indicating the proportion of surviving 
cells treated a t dose level j .  In order to obtain the value of Yij, we require 
the number of surviving cells to be estimated: this number is not recorded 
but is im portant when developing the model.
4.2 Initial model
We need to  describe the relationship formally between the various da ta  values in 
order to  construct a suitable model.
In addition to the d a ta  actually recorded, there are several unobserved variables 
we also need to include in order to  be able to make any useful inferences about 
them.
We shall trea t the number of control cells, NOi, per area on a slide as a Poisson 
count. The category of surviving cells, Yij, is derived from the proportion of 
surviving cells which depends on both the number of cells per area on a control 
slide and the number of surviving cells Nij per area for each dose level. The 
number of surviving cells depends on the initial cell density together with the 
probability of a cell dying pij and so will also be treated  as a Poisson count. The 
probability of a cell dying is assumed to have a logistic relationship against dose 




— Stochastic link 
" Deterministic link 
Stochastic node 
Logical node
Figure 4-1: Directed Acyclic Graph of initial model.
4.2.1 G raphical model
A directed acyclic graph showing the conditional dependencies of the variables 
detailed above is shown in Figure 4-1. The variables are represented by nodes. 
If the variable contains actual data collected then it is designated as a logical or 
deterministic node. Conversely a stochastic node denotes a variable representing 
unobserved information: it is the posterior distribution of these variables that 
the analysis is designed to estimate. In the graph, square nodes represent actual 
data and the circular ones indicate stochastic variables. The levels of indexing 
are represented by the boxes: for each drug there are n patients, with results on 
5 dose levels. At this stage the doses are assumed constant for each drug.
Purely deterministic or logical links are shown by dashed lines, stochastic 
dependencies by solid links.
Dose j
o□
4.2.2 The prior model
Since we are using a Bayesian analysis, each of the variables at the “top” of the 
model has to be described by a prior distribution. This distribution does not 
necessarily have to be a standard one but should describe the data adequately.
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We would like the prior distributions to  be sufficiently diffuse so th a t it gives 
reasonable weight to whichever region is supported by the da ta  likelihood. 
Roberts and Smith (1994) give as a sufficient condition th a t these distributions 
coincide. Ideally the posterior distribution will be influenced little by the prior 
distribution and achieve convergence according to  the da ta  available.
Control value, NOi
We assume th a t on the control slide, the cells are distributed according to a 
Poisson process with underlying density A* per unit area which is allowed to 
differ between patients. Since NOi is the average number of control cells per unit 
area over 10 such unit areas, the conditional distribution for NOi given Ai is thus 
given as 1/10 Pois(10A*).
U nderlying density o f control cells, A*
From observation of previous assay results, the mean number of control cells is 
around 100 with a wide variation. Owing to such variation between patients, 
rather than  have a common value, each patient has a separate A. Since A* can 
take any positive real value, it is assigned a Gamma distribution (r(2, ^ ) )  which 
has mean 100 and variance of 5000 which is large enough to  ensure sufficient 
probabilty over the range of likely values for N 0, for which the observed values 
range from <  1 to  over 200.
N um ber o f surviving cells, Nij
The Yij depends upon the number of surviving cells so this must also be modelled 
and given a prior distribution. The numbers of surviving cells are not recorded 
but each counter will ascertain this value in order to  calculate the proportion 
surviving after the various doses of drugs have been added. Cells may be counted 
accurately a t low survival since interest is focused around the 90% kill rate. 
Unlike the NOi, only one grid in the microscope eyepiece is used to  estim ate this 












Figure 4-2: Probability of a cell dying
is given as Pois(Aj). After drugs have been added, the Nij now depend on two 
things: the expected number of control cells and the probability of a cell dying. 
The first of these is governed by A* and the second by p^. Thus is given a
conditional distribution given and of Pois((l — Pij)X{).
P ro b a b il i ty  o f a  cell dy ing , pij
The probability of a cell dying p^ at a particular dose, Xij , is modelled logistically 
since when no drug is added, it is assumed that all cells survive and at a 
sufficiently high dose all cells are killed. A typical example cell morbidity is 
shown in Figure 4-2.
There are two parameters which control the shape of this curve, the location and 
slope. We suppose the probability p of a cell dying at log10 dose x  satisfies
log —- -  =  a +  bx, (4.1)
1 ~ P
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We can re-express this as:
log —^— =  a +  bx* +  b(x — x*). (4.2)
1 - p
where x* is the LC90 for the particular patient. At x  =  x* we have p =  0.9 so 
we now have
log =  a +  bx*. (4.3)
Substituting this back into Equation 4.2 we obtain
log , PlJ =  log 9 +  b(xi - x * ) ,  (4.4)
1 -  Pij
which is a more convenient form to work with since we are primarily interested 
in estim ating the LC90.
Since p ^  is a purely arithm etic function calculated for convenience as a param eter 
for the prior distribution of Nij , it does not require any conditional distribution 
to  be specified.
Slope o f the cell survival curve, Bi
The slope of the cell survival curve indicates whether there is a sharp response
or otherwise to the drug being tested over the assay range. Since there is little
information about Bi  and it is a “founder” node, it has been given a prior with a 
well dispersed Gamma distribution T ( |,  | )  (m ean=2, variance=16) to ensure it 
remains positive.
The dose, Xj
The dose is a predetermined value expressed on a log10 scale, calculated from the 
maximum concentration and dilution factors so th a t
Q
xi  =  >°gio jy z i j  where j  =  1 , 5 .  (4.5)
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Since this was initially assumed to be constant for each drug, the doses were 
labelled 1,2, ...,5 , with “1” being the lowest dose.
The LC90. X I
This is the value in which we are most interested since it indicates whether the 
drug being tested is likely to be effective for the patient. The units used depend 
upon the scale in use for the dose, Xj , (see below). This was given a fairly diffuse 
Normal prior distribution about the middle dose.
We define the prior distribution for X * to be
N  (log10(cd) -  3 log10(d), {log10(d)}2) • (4.6)
Since Equation 4.5 can be w ritten as
x j  =  loSioM ) -  3 logio(d) for j  =  1 ,..., 5, (4.7)
we see th a t this distribution is centred on x 3 with 2 standard deviations giving x \  
and x 5. This seems a reasonable model since the range of dose levels was selected 
to  include the LC90 for most subjects.
C ategory for proportion o f surviving cells, Y.\j
The are derived from the number of surviving cells divided by the number 
of cells on the control slide. The resulting estim ated proportion of surviving 
cells Nij/NOi a t dose level j  is categorised and represented by Y,\j. Hence, Y,\j 
can be described as a variable taking a categorical distribution depending on 
the proportion of surviving cells. The categories are not precise and do overlap; 
in order to  account for this, the probability of Y^  being recorded as a particular 
category depends on whether Nij/NOi falls within one of these overlapping ranges. 
The schematic diagram in Figure 4-3 gives a grapical representation showing all 
categories. If the proportion of surviving cells falls outside the allowable range 
of a category completely the probability of assignment to  th a t category is zero.
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Variable Prior \  Likelihood Description 
Distribution
Y1 * j Cat(njj/nOi) Recorded category of proportion surviving cells
NOi Pois(Aj) No. of control cells
Ntj Pois((l -p ijX i) No. surviving cells at dose j
Pij Deterministic Probability of a cell dying at dose j
A i r ( 2 ,£ ) Underlying rate for control cells
X j Deterministic Dose
x : jV(X3,{log10(<i)}2) LC90
Bi U U ) Slope of cell survival curve
Table 4.2: Variables included in the initial model with their prior or likelihood 
distributions.




1 05 Category / \  Category Category Category Category
£
0.0 4.5 5.5
Percentage o f  cells  Surviving
Figure 4-3: Diagrammatic representation of probability of recorded category given 
the proportion of surviving cells (not to scale).
Falling within any undisputed, non-overlapping area, yields a probability of 1 to 
assignment to this category. If the proportion falls within overlapping catergories, 
the probability of a category being recorded is a linear function dependent on the 
how close the proportion is to the category boundary.
For convenience, rather than use the initial category labels, the Y,\j take values of 
1,..., 5 where 1 denotes the lowest category of 0-5.5% survival and 5 the highest 
at > 70%.
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To calculate the probability for, say, P(Yij = 3 | Nij/NOi =  r^ ) , the values are:
0.0 Tij< 0.10
n j-  0.1 
0.12-0.1 0.10 <r{j< 0.12
1.0 0.12 ^Tij< 0.40
0.5—rij 
0.5—0.4 0.40 —rij <^ 0.50
0.0 0.50 <rij
The calculations are similar for all other values for Yij with the two extreme 
categories having just the 3 calculations. This distribution is denoted by the 
convention Y^  ~  Cat(riij/nOi).
4.3 M odel development
This initial model was used primarily as a test in order to  develop the final 
model detailed below in Section 4.4. A random d a ta  set was generated and used 
to  check whether the model as specified gave reliable results. O ther test da ta  from 
real examples was used to compare results with the manual graphical methods 
previously employed (See Section 2.2.3).
As more detailed information was received it became necessary to  extend the 
model to  incorporate the further categories for the proportion of cells surviving 
and the inclusion of more than  one set of results for each assay where available.
It is also desirable for the prior distribution to be sufficiently dispersed so th a t 
it will allocate a t least a m oderate level of probability to the region in which the 
da ta  likelihood is highest. If this is not the case, the posterior will be generated 
more by the prior than  by the data  and this is inappropriate in an application, 
such as this, where we have only weak prior beliefs. Inspection of both  the prior 
and posterior distributions and the corresponding likelihood indicate th a t this 
is achieved with varying degrees of success. Obviously, success will vary across 
patients, disease and drug type. Figure 4-4 shows an example prior and posterior
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-0.5 0.0 0.5 1.0 1.5 2.0 2.5
Figure 4-4: Density plots for (i) the prior distribution (top), (ii) the likelihood 
(middle) and (Hi) the resultant posterior distribution (bottom). Drug = TAX, 
variable — X*(\og10 LC90), patient=24-
distribution together with the likelihood of the data (calculated up to a constant 
of proportionality).
In order to include information learned about founder nodes from the whole data 
set during the MCMC simulation, a further layer of nodes is added. Thus, for 
example, the slopes Bi may be modelled by a fairly compact distribution when 
there is evidence in the data that different subjects all have similar slopes, but 
the location for this compact distribution is given considerable freedom in the 
prior. As the analysis is conducted, information about slopes Bi for individuals 
is fed back through the model structure. This enables these nodes to depend 







1) 0 0 - 2%
2) 5 0.1- 8%
3) 10 2 - 12%
4) 15 10- 25%
5) 30 15- 45%
6) 45 30- 60%
7) 60 45 -100%
8) 100 >  60%
Table 4.3: Categories used to denote proportion of surviving cells
4.4 Developm ent of final m odel
As further information and additional da ta  were made available, it became 
necessary to make im portant changes to the initial basic model and the model in 
final use is described in this section.
W hilst the fundamental structure remains similar, the inclusion of all recorded 
results rendered necessary a further level of indexing. There are now patients 
i =  l , . . . ,n ,  doses j  =  1 ,..., 5 and replicates k =  1, ...4. E xtra  nodes were also 
added as the da ta  structure gained complexity.
4.4.1 Additional cell survival categories
In order to record data  more accurately, more categories indicating cell survival 
have been introduced. In to tal eight categories were used, w ith greater attention 
still being paid to low cell survival rates. The new categories are given in Table 4.3 
and depicted in Figure 4-5. The probability calculations for each of these values 
with the additional categories are shown in Table 4.4.
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i~ijk —  NOik/Nijk Pr(Yijk —  Vijkl'f'ijk —  NOik/Nijk)
0.0 -  0.001 P ( Y i= 1) = 1.0
0.001 -  0.05 p { y » k — 1) —
0.05—r ijh  
0.05-0 .001 P ( Y i i k =  2) =
r i j k -0 .0 0 1  
0 .05-0 .001
0.05 -  0.08 P ( Y i — 2) —
0 .08—r ij  k
0 .08-0 .05 P ( Y i i k =  3) =
rijjfe—0-05 
0 .0 8 -0 .0 5
0.08 -  0.10 p ( y , j k = 3) = 1.0
0.10 -  0.12 P ( Y i = 3) =
0 .1 2 -r ijfc
0 .12 -0 .10 P ( Y i j k =  4) =
rijA.-0 .1 0
0 .1 2 -0 .1 0
0 .1 2 -0 .1 5 P ( Y i j k = 4) = 1.00
0.15 -  0.25 P ( X i = 4) =
0 .2 5 -r ijfc
0 . 2 5 - 0.15 P ( Y i i =  5) =
riifc-0 .15
0 . 2 5 - 0 .15
0.25 -  0.30 P { Y i = 5) = 1.0
0.30 -  0.45 P ( Y i = 5) =
0.45—rjjfc 
0 .45-0 .30 P ( Y i j k =  6) =
r i i k -  0.30 
0 .4 5 -0 .3 0
0.45 -  0.60 P ( Y , k = 6) =
0.60—ty,*. 
0 .60-0 .45 P ( Y i j k =  7) =
r»jfc—0.45 
0 .6 0 -0 .4 5
0.60 -  1.00 P { Y i = 7) =
1 .0 0 -r iifc
1 .00-0 .60 P ( Y i j k =  8) =
0.60
1 .00-0 .60
>  1.00 P ( Y i j k = 8) = 1.0
Table 4.4: Probability calculations for Pr(Yijk =  VijkVijk — Nijk/NOik).
Categories not shown have zero probability.
80/100
100
Percentage of cells Surviving
Figure 4-5: Diagrammatic representation of the eight categories of surviving cells 
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Table 4.5: Table showing ordering of replicates, slides and counters.
4.4.2 Replication of assay results
The new model incorporates information from all the da ta  collected and not just 
one set of assay results. From Chapter 2, it is stated  th a t up to  four sets of results 
are recorded from the assays performed. Since there are two assays performed and 
two scientists independently categorising cell survival, a further level of indexing 
is required for each patient. The first two replicates concern slide one counted 
twice by different scientists. The third and fourth replicates concern the second 
slide again counted twice with the same counters as for slide one. See Table 4.5 
for the ordering of indices.
There are now up to two control values supplied which have to  be to  dealt with. 
While initially only one value was given, in the later data, up to  two values are 
recorded, one for each assay performed. If the second value is similar to  the 
first then only the initial value is given, otherwise there are two values. Each 
scientist works with his or her own control values but th a t of the second scientist 
is not recorded. Hence NOik, k =  1,.., 4, can now have up to  4 values per patient 
depending on how many sets of assay results are noted, but only up to 2 control 
values are recorded for any one patient: NOn is always given. W here replicate 3 
exists, NQis is either given or assigned to  be the same value as NOn since if the 
two control values are similar, only the first one is noted. The values for N0i2 and 
AT0i4 are not given and are therefore treated as stochastic nodes and therefore 
simulated in order to obtain estimates for them.
There are thus up to four sets of results for the control values NOik, the number 
of surviving cells, Nijk and the proportion surviving Y ^ . Since the control values 
can therefore differ between each replicate, the value for A, the underlying cell 
density, was allowed to differ within patients as well as between them. Whereas in
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the initial model, these values were independent between patients, they are now 
only conditionally independent given the relevant hyper-prior, see Section 4.4.4 
below. The A^s show good agreement within patient but, as in the control value, 
there is considerable variation across all patients.
4.4.3 Variable dose levels
The five doses of a particular drug were initially held to  be constant over all 
subjects, however, dose levels have changed as further knowledge about their 
behaviour became available. The nodes Xij, j  =  1 ,...,5  are still founder da ta  
nodes but their values are now allowed to  differ between patients.
4.4.4 Hyper-priors
The final model thus has essentially the same structure as the initial model but 
with a further level of indexing required to  incorporate all the replicates. Extra 
nodes have been added at the founder level in order to  obtain a better model. 
These nodes are denoted hyper-priors and correspond to  the param eters required 
to  describe the prior distribution of the initial founder nodes.
We would like the prior distributions for the original founder nodes not to be too 
influential in the final summaries: it is useful to  incorporate information gleaned 
from the da ta  in the form of fairly informative priors rather than  use improper 
prior distributions. In this way, by letting the distributions of these nodes have a 
stochastic dependency on the actual param eters of their prior distributions, there 
can be a “feedback” of information which is not possible in the initial model.
For the founder nodes with a Gamma prior distribution, and Bi, the shape 
param eter was fixed and the scale parameters, 0\  and 0b, respectively were allowed 
to vary in order to give a fairly diffuse conditional prior distribution. The other 
founder node, X*  had been given a Normal distribution and hence has two hyper­
prior param eters associated with it: fix* and
The new hyper-prior nodes themselves require prior distributions and these are
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Variable Prior Distribution Description
Yijk C&t(nijk/nOik) Recorded category of proportion surviving cells
N 0 ik Average no. of control cells per unit area
Mik Pois(lOAj) No. of control cells in 10 unit areas
Nijk Pois((l — Pijk)^i) No. surviving cells a t dose j  in 1 unit area
Pij Deterministic Prob. of a cell dying a t dose j  function of X *,
A < r(2, £ ) Underlying density of control cells
ex r(4,0.8) Hyper-prior: scale param eter for distn of Ai
Xij Deterministic Dose
*<* N(fl, LC90
Px* N (  0 ,100) Hyper-prior: mean for X*
<v2 r(o.oi,o.oi) Hyper-prior: variance for X*
Bi r(H) Slope of cell survival curve
Ob r(U) Hyper-prior: scale param eter for distn of bi
Table 4.6: Variables included in the final model with their prior distributions.
given in Table 4.6. The distribution for p,x* has been chosen as a N(0,100), whilst 
the other nodes are constrained to remain positive and have been given Gamma 
distributions (see Table 4.6 for param eter values).
The conditional dependencies do not alter except a t the previous founder level. 
These nodes are no longer founders since they are now conditional on their 
respective parents: the hyper-priors which have now become the new founder 
nodes.











Figure 4-6: Directed Acyclic Graph of final model
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Chapter 5 
M odel Im plem entation
Having now defined a model which describes the data, the next task is to 
implement it. There are various options available and two approaches were 
actually used. The first approach was to use a publicly available package and 
the second meant writing a customised program. Obviously writing a program 
specifically designed for this problem meant being able to  incorporate all the 
features of the d a ta  required. Despite the extra time required to  develop such 
software, the gains in terms of flexibility to add extra features and make changes 
easily make this the more useful option.
5.1 BUGS
The initial model as defined in C hapter 4 was specified in the com puter package 
BUGS - Bayesian inference Using Gibbs Sampling (Spiegelhalter et al. 1994). 
This package assumes a full probability model in which all quantities are treated 
as random  variables. The data  are then conditioned on in order to obtain a 
posterior distribution. Marginalising over this distribution in order to obtain 
inferences on the main quantities of interest is carried out using Gibbs sampling.
This program allows you to calculate summaries and examine the resulting chains 
generated. However, care needs to be take as convergence is not guaranteed in 
any fixed number of iterations. Resultant chains need to  be saved and stored
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in order to be able to assess their reliability properly. Separate diagnostics need 
to be performed on these chains to ensure convergence and determine whether 
the chain has been mixing well. Simple graphs are available within the package 
but more sophisticated techniques need to be done externally. One such package 
capable of providing implementations of several convergence diagnostics is CODA 
(Best et al. 1996).
Although BUGS, and its successor winBUGS, appeared to  offer an initial solution 
to our problem and was used to test the aptness of the initial model using a 
randomly generated test da ta  set, it was too slow to be of use. Given the vast 
number of runs to be made, efficiency was a m ajor concern which meant looking 
a t alternative methods.
5.2 Customised program - initial version
The alternative to using a commercially available package is to  write a problem 
specific program which is capable of dealing with all the features of the data  and 
is easily extendable.
Since not all the prior distributions specified were conjugate, these full conditional 
distributions could not be evaluated conveniently and hence a Gibbs sampler was 
not used. The rather cumbersome non-standard prior distribution for made 
the Metropolis Hastings method a far more economical algorithm to implement.
This program was w ritten in ANSI C and initially tested using a randomly 
generated data  set. Once this was found to be working satisfactorily, the first 
available da ta  set was then used. The program gave intuitive results, the 
estim ated LC90s being calculated at a slightly lower dosage than  the manual 
graphical technique previously employed as described in C hapter 2 where the 
assay results were plotted, a curve fitted through the ranges of cell survival, and 
the LC90 was estim ated by reading from the :r-axis the dose a t which there was 
estim ated 10% cell survival. MCMC methods enable us to  calculate estimates of 
the posterior intervals.
W hen the data  set was finalised, some of the initial assumptions had to  be changed
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and the model was extended as discussed in Section 4.4 in order to incorporate 
these changes. “Hyper-priors” were introduced — a further set of founder nodes 
a t the top level of the model with very diffuse prior distributions which enabled 
the previous founder nodes to  be data  driven and to reduce the influence of the 
prior distributions.
The model for the data  has undergone several developments from the initial one 
specified and it is on the final model, as shown in Figure 4-6, th a t the rest of the 
chapter is based.
5.3 Program Algorithm
The program breaks down into 4 main sections:
•  Read in da ta  into appropriate structures
•  Initialise variables
•  Updating the Markov chain
•  Compute and report results
5.4 Reading data
Since each drug is dealt with separately, only those records relating to  the current 
drug are stored. D ata are read in to appropriate structures and indicator variables 
are used to denote missing da ta  values which are then treated in the same manner 
as a stochastic node.
5.5 Initialisation
Each stochastic node and missing da ta  value has to be initialised before any 
analysis can be attem pted. This is done from the “bottom ” level upwards.
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Starting values for each of the founder nodes, i.e., 9\, 6b, n x* and cr^., were 
generated randomly from their prior distributions using methods described by 
Ripley (1987).
The offspring to these nodes (A*, bi, x*) also have their initial values generated 
from their prior distributions but allowing the values from their hyper-priors to 
be utilised.
Initialisation of NOik differs depending on which replicate is being considered and 
whether there are one or two control values given, see Section 4.4.2. Replicate 
1 is always given: if there is a second replicate, then n 0 ;2  is initialised to have 
the same value as nOn. If the third replicate exists and nOi3 is not given, then 
it is assumed to have the same value as nO i^ otherwise a separate value would 
be recorded. The fourth replicate is initially given the same value as nO^ if it is 
available or otherwise.
The underlying number of control cells over 10 areas, m ^ , is initialised to be 
10 x n0ik .
The probability of a cell dying pijk is a straightforward calculation involving x ^ ,  
X*  and Bi (see Equation 4.4).
Once the nO^s have been determined, together with the category for the 
proportion of surviving cells, yijk, the number of surviving cells, riijk, can then 
be given starting  values. The n ^ s  have constraints governing their legitimate 
range given by the extreme values of the survival categories, y^k, multiplied by 
nOjfc. Starting values are thus set to the mid-point of this range. If the recorded 
category is “8” , i.e. representing >  60% of surviving cells, there is no upper 
bound, and so starting  values in this case range from 0.6 x nOik +  20. Although 
the value “20” is somewhat arbitrary, subsequent analyses show this value is 
unim portant.
The survival categories, y^k, are mostly recorded. Missing observations are set 
to the value of next replicate with a non-missing value for th a t particular drug 
dose. If there are no such values then this is set to  the category for the replicate 
a t the previous dose level. We could remove such Yijk from the graphical model 
but it is convenient to trea t these as random variables and update them  as the
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notation remains consistent and it facilitates the estimation of the cell survival 
curve and hence the LC90.
5.6 Updating in the Markov Chain
Once all the values have been initialised, the Markov chain can then be 
constructed. The Metropolis-Hastings Algorithm as described in Section 3.3.1 
has been used.
5.6.1 Proposals
Proposal distributions depend on the type of node being updated. If jumps 
are too small, the simulation moves very slowly through the target distribution; 
conversely big jum ps will be rarely accepted, slowing the rate  of convergence.
For a continuous variable with no constraints, a Normal distribution, with mean 0 
and variance selected to ensure acceptance rates averaging around 40% is used to 
generate a proposal value. W hilst Muller (1993) proposed a scheme of accepting 
proposals with rates between 20%-80%, Roberts (1995) gives a guideline of 15%- 
50% in preference to this. Gelman et al. (1996a) proceed to  show an optimal 
acceptance rate is roughly 40% and give a theoretical justification in Gelman 
et al. (1996b) but concede other schemes work as well bu t may converge more 
slowly. In practice, precise acceptance rates are unattainable for every simulation 
being carried out and therefore, of the variables monitored, the target acceptance 
rate  around 40% was not always achieved with some rates differing considerably. 
This was usually due to the restrictive range limits of legitimate values especially 
for discrete variables.
For variables with a Gamma prior distribution, a Normal distribution is still 
used to generate proposals but negative proposed values are discarded and a new 
proposal generated if necessary. This effectively gives a left truncated Normal 
distribution and care needs to  be taken when calculating transition probabilities 
in this case. We used a Normal kernal here to  produce proposal values since
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generating a random variable with a gamma distribution was more expensive 
computationally especially when there is a non-integer shape param eter.
Proposal values for discrete variables are generated to be uniformly distributed 
in the range x  — k, .. . ,x  — l ,x  +  1, ...,x  +  k , where x  is the current variable 
and k is the largest sized jum p allowed; this value is predetermined to give 
reasonable acceptance rates. If x  ±  k falls outside the allowable range, k  is 
decreased so there will be two different values, kmin and kmax. Proposals, x' 
will then fall within (x — kmin) < x' < (x +  kmax)- The possible proposed 
values are still uniformly distributed either side of x  bu t are no longer uniformly 
distributed over the whole range so that: P  ((x — kmin) < X '  < x) =  0.5 and
Occasionally the range of valid values is so narrow so th a t proposals are 
necessarily the same as the current value, this may happen if both  NOik and 
Yijk have small values. In these cases, no update is attem pted.
Having non-symmetric proposal distributions will affect the transition probability 
calculations (see below).
5.6.2 Acceptance probabilities
The acceptance probability, a, of a proposed value, x' say, is the product of two 
quantities: the ratio of the posteriors with regard to  the proposed value and the 
ratio of the transition probabilities. If this quantity is greater than  1, a  takes the 
value of 1, i.e.:
P  ((x < X '  < ( X  +  k m a x ) )  =  0.5.
a(x, x') — min ( 1 (5.1)
where 7r(x ') is the product of the prior and the likelihood of the data and q(x ', x) 
is the probability of proposing a value x  from x'.
If the proposal distribution is symmetric, then the transition probabilities are 
equal and therefore do not need to be evaluated as they cancel. However, 
proposals with a non-symmetric distribution, i.e. those with range constraints,
will still need the transition probabilities to be calculated.
5.6.3 Transition probabilities
If the variable has a Gamma prior distribution then proposals need to be 
positive. A proposal is generated by adding to the current value, for example 
cr~*2, a randomly generated value from a Normal distribution with mean zero and 
standard deviation s to obtain . If is negative another random number 
is generated until the proposed value is valid. Clearly these proposed values 
do not form a standard Normal distribution since this distribution is effectively 
truncated at its lower tail since negative values of a magnitude greater than  <r”„2 
are invalid. Therefore, in order to compute
we need to re-scale the proposal distribution to have unit area since values are 
invalid over its lower tail.
















The cdf of the standardised Normal distribution is computed using the algorithm 
given by Hastings (1955) based on a polynomial approximation P (z)  = $ (z )  +  e. 
The error term , e, is such th a t |e(:r)| <  1.5 x 10-7 .
For discrete variables, a similar approach is adopted in th a t there are often range 
limits. The maximum proposal size is predetermined according to  the valid range 
in order to  give acceptance rates of around 40% (see Section 5.6.1). The proposed 
value, x' say, is obtained by adding a uniform random  variable to x  over the range 
{—k , ..., — 1 ,1 ,..., +&}. If the maximum jum p size allowed takes the proposed 
value outside the valid range then this probability calculation is modified over 
the range {kmin,..., —1,1 ,..., +fcmax} so th a t P (x ' > x) =  P ( x ' < x) =  0.5. So, 
suppose, for example x' > x  where x' has fcmax(£') and x  has kmin(x) , then
q(xf,x )  _  0 .5 /kmax(xf)
q (x ,x ‘) 0.5/ k min(x)
"minyK
kmax 
If the current value is already at the minimum allowed value then the proposed 
value can obviously be only greater than this, and analogeously for the maximum.
5.6.4 Acceptance probability calculations
For com putational ease, logs have been taken of the posterior part of the 
expression Equation 5.1 to  reduce a product to a sum which can be computed 
more efficiently as computer addition is significantly quicker than  multiplication 
(Press et al. 1988).
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N otation
The following conventions have been used throughout the following section.
P  — Number of patients
D — Number of doses - this is always 5
Ri — Number of replicates for patient i (up to  4)
tt( x ) — Likelihood of the dataset and current param eter values
Pijk ~  Probability of a cell dying for patient dose j ,  replicate k
_  9 exp [bjjxjjk ~  x *)]
10 +  exp [bi(xijk -  x *)]'
Where is used, this denotes a substitution of one of the variables
bi or x* by its proposed value b' or x'*.
5.6.5 Full conditional probability distribution
It is convenient to  state  the conditional probability for the full model given the 
observed da ta  from which subsequent calculations are derived. The probability 




I I  [ f \k \0 x ik \0 \ ) fM ik\\ik{mik\Xik)fNoik\Mik{nOik\mik)
D
n  {fpijk\xik,x*,Bi(Pijk\xik, X* , b i ) f Ntjk\ptjkjXik{nijk\pijk, \ ik)
j =l
fYi j k\Ni jk,NQik {yi jk\ni jk'>  }  • (5.2)
50
The conditional probability of unknown variables given observed data  is 
proportional to this quantity. All further calculations are derived from this 
expression. Terms not involving the variable being updated cancel when forming 
ratios leaving a much reduced formula.
5.6.6 Acceptance probability for an update of cr2*
We wish to calculate the ratio of probabilities 'k ( x ' ) / ,k { x ) where the numerator 
refers to the probability of the whole dataset but substituting a proposal for the 
current value being updated, and the denominator refers to  the probability of the 
current set of values.
Given a~} has prior distribution o~* ~  T(r, v), where r  and v  are constants with 
values: r  =  0.01, v  =  0.01, we get mean and variance of 1 and 100 respectively 








l0S Trie} =  (r “  1)(1°S ° x '  ~  loS a x*2 ) +  ^(<V2 -  * / )
1
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We then multiply this by the transition probability ratio
gps'. x )  _ $ )
q(x ,x')  f
to  obtain the acceptance probability of the proposed value. Here s is the standard 
deviation of the Normal kernel used to generate proposals.
The probability, a (x ' ,x ) ,  of accepting the proposed value for cr~,? is then:
min 1
5.6.7 Acceptance probability for an update of /xx*
The prior distribution given to fix* is fix* ~  N (m ,v ) .  Hence the proposal values 
are not constrained and so have symmetric transition probabilities which cancel 
out and do not need to  be calculated and so a  =  min (1 ,7r(x')/7r(x)).
7r(x')
7 r ( x )
/* .. ( / 4 o n w , , ,  (x*i<v 2> & ')
i=l
f n x * < T ~ ? , H X * ( X i \ a x *  » V x * )
i — 1
j _ e x p  (  n _ L eXnV2^ UeXP^ 2 v P V 2 J
i — 1
_ L _ p x d  (  m>*'I T T ^ - e x D  (  ' I *V2™ xp  ^ 2 . p v 2 y
i=l
Taking logs:
[(/ix. -  m )2 -  (/i'x. -  m )2]
+ ^ 2 "  X [(Xi -  Mx-)2 -  (X,* -  l l ' x ' f ]
2(Jl '  ■ i x  1 = 1
The probability of accepting a proposed value for \ix+ is thus: 
a  =  min ( 1, ^  [(//*. -  m f  -  (#£. -  m )2] +  X I  [(x>? -  ^ * ) 2 _  (x«r ~  ^ ’)2]
\  x * i= l
5.6.8 Acceptance probability for an update of 0&
6b has been given prior distribution Of, r s j  r (r, r;) with r  =  J and t> =  ^  giving a 
mean of 10 and a variance of 400 in order to ensure a sufficient range of suitable 
values for this parameter.
/nwail/WM*)
TTpr ) = _________ i= 1___________
7r(x)
i= l
ffaO'b{T 1} exp (—
f a t f "  exp ( - « * )  exP ( 1 7 )
Taking logs:
log =  (r  “  !) loS eb ~  (T ~  !) log Ob ~  v0'b +  v6b'K[x)
+  X  ( - f c  log 6>£ +  fc log ^  ^
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The ratio of transition probabilities is:
g(3, h) *  (*)
\  s  J
W here s is the standard deviation of the Normal kernel used to generate 
proposals. The acceptance probability a  is calculated as before.
5.6.9 Acceptance probability for updating 6 \




« r r ( * A )
11 exp
1 ^)0^  11 exp ( - v 9 x )  n n
Taking logs:
log = (t - 1 )  log 9X — (r — 1) log 0\ -  v6'x +  v9x
7T{X)
The ratio of transition probabilities is:
qJM a) =
a, 8\) $
W here s is the standard deviation of the Normal kernel used to generate 
proposals. The acceptance probability a  is calculated as before.
5.6.10 Acceptance probability for updating b{
The prior conditional distribution for bi is ~  r(/Cfc, where the shape param eter 
Kb = 0.25. The skew shape of this distribution makes it not improbable for the 
presence of steep slopes.
D Rj
X i j  {j^ijk |^ ik ) bj^Xj  ) Xi j )
j=lk=l
D Rj
ij i.B'ijkl^iki b{, X{ , Xij)
j=lk=l
exp ( ^ )  
exp (jjjjf)
D Rj
n n  [Ai*(i  - P i j k ) Y iii’ exp [—Aifc( i -  p'ijk)} / n ijk\
j=ik=i 
X  D R i
J i l l  “  P w ) T iik exp [—Aifc(l -  pijk)) / n ijk\ 
j=ik= 1
=  ( / 6 6 - l ) ( l o g ^ - l o g f e i )  +  ~ ( f e i - 6 j )
Vb
D Ri
+ E E  \jlijk [lo§(AiA:(l Pijk)) iog(Aifc(l Pijk))]
j = 1 k= 1
+AiA: [(1 ~  Pijk) ~  (1 ~  Pijk)] }
7r(xl)
ir(x)





=  (1C - 1 )  log ( J ) + I ( 6 i - 6 ' )
+  E E {  log ( ! + Ai*(Pv* _  P«‘ )}j=l fc=l  ^ '  Pijk/ )
The ratio of transition probabilities is:
Q % bi)  » ( * )  
$ ( 7 )
W here s is the standard deviation of the Normal kernel used to generate 
proposals. The acceptance probability a  is calculated as before.
5.6.11 Acceptance probability for updating X *
The prior conditional distribution for X * is N(/j,x*,
D Rj
f x - l  m m *  k \ X i k , X * ( j l ' i j k \ ' E i k ' )  x i Aik)
7t{x ') j = 1 k= 1
ir(x) D Rj
° m m ,  k\xik,x?,Bi,\ik {riijk\xik, x*,bi, A ik)
j=ik= 1
 1 - exp
y w : e x p i  2 ;
p i  2 1
1 1 1 1 ---------r - 1--------exp 1  “  )





1 7r(a?/) 1 / */ \ 2 1 / * n2
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D R
“1“ ^   ^ ^   ^ \ j l j j k  log[A ifc(l P i j k ) \  ^ i j k  log[A jfc(l P i j k ) ]
j = 1 k = 1
— — P i j k ) d~ — P i j k ) }
2 ^ 2 7  I K  -  ^ ' ) 2 -  «  -  M 2]
"1" Ai k i j P i j k  P i j k )
D R
+EE nijk log
j = 1 fc=i
■1 P i j k
_1 P i j k .
Since X* can take any value, the transition probabilities are symmetric and 
therefore do not need to be calculated as q(x*\ x*)/ q(x*, x*') — 1 .
5.6.12 Acceptance probability for updating A,•*
The prior conditional distribution for A^, the underlying ra te  of all cells, is 
A ik ~  r(/cA,E ) .
D
f>.\<)x(KklQ\) f M \ \ ( ’nrH k \ K k ) Y l ^ N \>' -B ,X - ,x (n i]l:\Kk> X 'i i
’T(g') =  __________________________ _________________________________
7r(a:) -0
f \ \ e x { ^ i k \ 9 \ )  f M \ x ( j n i k \ ^ i k ) Y [ f N \ X t B , X * , x { p > i j k \ X i k i  b i , X * , X i j )
j = 1
^ - ‘W ) exp ( ^ )
nu‘A:-
X
j - l  n i j k
Taking logs
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log =  (Ait -  A-*) j -  + (ka -  1) (log A'* -  log Ait)
+m.t[log(10A'J.) -  log(lOAit)] + 10(Ait -  \'ik)
D
+  ^ 2  Uii k log
j = i
P i j k )
, \ k 0 ~  P i j k ) .
i \ k  P i j k )  A
1 D
—  4- 10 + ^ ( 1  -  Pijk)
6x u
(Ait -  Kk)
+
D
KX -  1 +  m ijk +  n ijk 
j -1
l o g ^
*ik
The transition probabilities are:
g (A 't .A it )  =  $ ( * * )
? (A it, X i k )  $
W here s is the standard deviation of the Normal kernel used to generate
proposals. The acceptance probability a  is calculated as previously described.
5.6.13 Acceptance probability for updating
The prior conditional distribution for N i j k  is given as N ^ k  r s j  Pois((l P i j k ^ i k )  •
The ratio of likelihoods is calculated as follows:
n { x ’) _  I n \ \ ,b ,x ,x * i n i j k \ ^ i k ,  h ,  x * , X i j ) f Y \ N , N o ( y i j k \ n j j k , nOik )
^{pc)  fN \ \ , B , X , X *  (P'ijk > •^i j )fY\N,No(jJi j k\ '^' i jki  ^0*fc)
[A tfctl-PiiO ] e x p  _  P i j k ^  f Y W m^ { y i j k \n'i j k , n O iA:)
  i j  k ' J
" nPife!°  eXP (— “  Pijk)) fY\N,m(yijk\^ijkj nQik)
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if 'R'ijk ^  ^ijk •
t t Q e Q  _  [ A j f c ( l  -  Pi jk)] iriijk~ nijk) fY \N ,m ( y i j k \ r i i j k ,nOik)
n  *
if n i j k  >  m!i j k  :
fY\N,No(yijkWijk  ^n®ik) 
fY\N,No{yijk\'^,ijk5 ^Oifc)
The value for /riAr.wofejJfcKjA;, ™0;fc may be zero if n'i j k  falls outside the valid 
range given y i j k  and nOfc. In this case the proposed value, n ,ij k  is not adopted.
Transition probabilities are calculated as follows: If riijk ±  k, where k refers 
to the maximum jum p size perm itted, falls within the legitimate range then the 
proposal probabilities are uniformly distributed over ( r i i j k — k ) , ... ,  ( r i i j k — 1 ), ( r i i j k +  
1 ) , ..., ( r i i j k  +  k) . Similarly for n'ij k . If this is the case for both  r i i j k  and n'ij k  then 
qin'ijk, riijk) =  q(n i j k ^ i j k) =  1 / 2 k, and so the ratio of transition probabilities is 
1 .
However, if the transition probabilities cease to be 1 /2k owing to range constraints 
(as described in page 49) then this ratio is no longer 1 and must be calculated.
5.6.14 Acceptance probability for updating
The conditional probability for is Pois(10A;jt). The ratio of likelihoods is 
calculated as follows:
D
fM\\(m'ik\ >^ik)  TT/y | w ,  a t o  ( y i j k  | r i i j k ,  m 'ik )
r r ( x ' )  _  j = i
fM\x('nrHk\^ik)Y[fy\N,No(yijk\nijk, TTlik)
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1^0y , ,fc e x p ( - 10A<fe)/y|^IM(2/iifc|wijjb, m'ik)
 i k  *_________________________________________________________
ex p (-1 0 A ijfe) /y |^ >Af(2/»jjfe|wij/b, m ik)
if m'ik > m ik : 
7r(x ')
k {x )
if m ifc >  m'ik :
7r(x')
7r(x)
The transition probabilities are calculated in a similar m anner to  th a t in the 
updating of riijk•
5.6.15 A cceptance probability for updating
The category of surviving cells has been given a categorical distribution dependent 
on n O i k  and r i i j k .  Details of calculating P ( Y i j k  =  y i j k \ N i j k  =  n i j k ,  N 0 i k  =  n O i k )  
are given in Table 4.4.
n l y ' i j k )  _  fYijk\Nijk,NOik (y ' i j k \ n i j k , rcOjfc)
V i j k ) f Y i j k \ N i j k , N Q i k  { V i j k l ^ i j k i  ^-0i k )
Transition probabilities are calculated in a similar m anner to  th a t of rriik and 
f^ijk •
x ' n fY\N,M(yjjk\nijk,rriik) 
1 1  f y ^ m i y i j k l r i i j k ,  m i k )
II ~  q)
9=0
(1 0 Att)m“ - m“  x J ]  « - , )
9= 0
TT f Y \ N , M { y i j k \ n i j k i  m j k )  
jJifY\N,M{yijk\nijk,
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5.7 Running the Markov Chain
Having obtained all the formulae required in order to perform updates in the 
Markov chain, these need to be implemented efficiently to  try  and reduce 
computing time.
Also, given the volume of d a ta  to be analysed, we wish to reach convergence as 
soon as possible. This involves monitoring acceptance rates and choosing suitable 
sized jum ps to try  and ensure the chain moves freely without getting stuck and 
th a t it has reached all parts of its posterior density. Before any reliable inferences 
can be drawn we have to  be sure the chain has converged. This is done using 
convergence diagnostics within the package CODA.
This is dealt w ith in the following Chapter.
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Chapter 6
M CM C Convergence and 
Validation
There are several im portant implementation issues associated with MCMC 
methods. The first involves the choice of sampler: we have chosen the Metropolis- 
Hastings algorithm because of the type of distributions being used in the model 
and the convenience of implementation this m ethod offers when dealing with non­
standard and non-conjugate distributions. O ther im portant points to deal with 
include the choice of starting values, the length of the burn-in, acceptance rates 
of proposal values, and the number of iterations required in order to  produce 
reliable estimates.
These factors are inter-related and all have some effect on the rate a t which 
convergence occurs. W hilst having over dispersed starting values may delay 
convergence, they are a useful tool in determining convergence by comparing 
the results of running more than  one chain (Gelman & Rubin 1992).
Various methods have been proposed to assess convergence and some of these 
which have been implemented in CODA (Best et al. 1995) were used to  test 
some of the Markov chains produced. These techniques are looked a t in more 
detail in Section 6.3. Brooks & Roberts (1999) and Cowles & Carlin (1996) give 
a comprehensive overview of other diagnostic methods in use and a comparative 
review of their applicability and ease of use.
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Given the volume of da ta  to be processed and hence the number of calculations 
involved, efforts are made to ensure the methods employed are efficient and th a t 
the chain mixes well to accelerate convergence.
6.1 Starting values
W hilst starting  values are theoretically unim portant as, given any value, the chain 
will converge eventually, they may affect time to  convergence (for example, see 
Raftery h  Lewis 1992a). Thus it is desirable to have values which are not so far 
away from the posterior distribution th a t this adversely affects the rate a t which 
the chain achieves convergence. Since the prior distribution should support the 
posterior probability distribution, using starting  values generated randomly from 
the prior distribution, although diffuse, should not affect convergence.
This issue is usually a minor one with the continuous variables in this particular 
problem, but care needs to be taken with values which have range constraints. 
For example, when initialising the Y^ks, if the control value, NOik, is small 
and an inappropriate starting value is used, the chain may become stuck since 
the posterior distribution no longer assigns any probability to  neighbouring 
categories.
This became evident with one patient with a particularly small control value of 
rc0 30)i =  n 0 3o,3 =  6  and a set of cell survival categories (Yso^k) with missing 
results as follows:
Dose 1 2 3 4 5
Slide 1, Counter A 8 8 ? ? ?
Counter B 7 7 5 1 1
Slide 2 , Counter A 8 8 ? ? ?
Counter B 8 8 5 1 1
W hen the missing categories are updated, it is impossible to make a jum p to 
category 1  to any of the others or vice versa as the d a ta  do not support any 
probability for the intermediate categories 2 and 3.
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Category Y^k Proportion surviving Possible N i j ^  values
8 60%+ 5, 6 , 7, ...
7 45-100% 3,4,5 , 6
6 30-60% 2,3
5 15-45% 1 , 2
4 10-25% 1
3 2 -1 2 % -
2 0 .1 -8 % -
1 0 -2 % 0
Table 6.1: Possible values for surviving cells, for  each category of proportion
surviving
In rare circumstances, such as this example, the chain may  become reducible since 
the nOij is small and can take integer values only, hence not all categories of 
y^k  are possible, see Table 6.1.
Under such circumstances, the updating scheme used to generate proposals 
prohibits movement between some categories as only steps of size ± 1  can be 
made when updating Yijk. This may be circumvented by changing the updating 
scheme to generate proposals over the whole range of categories ra ther than  just 
the neighbouring ones. However, this would be rather wasteful as the proposals 
would be rejected most of the time.
The main problems with reducibility here is the inability for the chain to  move 
from invalid or improbable categories to  areas with of high probability if the 
intervening categories have no associated probability. Hence, in this particular 
example it is im portant th a t starting  values for the missing Y^k categories are 
valid given nO^ and nijk so th a t any possible problems caused by reducibility are 
minimised. The chain may yield unreliable estimates otherwise as any proposed 
value for Y^k will be rejected since they will all be invalid. This prom pted the 
initialisation scheme as described in Section 5.5 rather than  simply assigning the 
category a t the previous dose level for missing values.
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Figure 6-1: Trace of Drug = VO, variable=6b.
6.2  A cc e p ta n c e  ra tes
As stated in Section 5.6.1 the rate at which proposals are accepted also affects 
the time taken to convergence. If the proposals are too small, the chain moves 
very slowly through the target distribution. If proposals are too extreme then 
they are rarely accepted.
Figure 6-1 shows three example plots constructed using different standard 
deviations for the proposal kernel used for updating variable Ob- The acceptance 
rates differ greatly depending on the standard deviation used: from top to bottom 
the acceptance rates for the traces are: a) 99%, b) 50% and c) 2.5%. If the 
standard deviation of the Normal kernel used to generate proposals is too small 
then the proposals are nearly always accepted and the chain “snakes” up and 
down and convergence is slow, as in the first trace shown. If the jumps are too
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big then the chain may get stuck for periods of time and the trace looks “blocky” 
(last trace). See Section 5.6.1 for a discussion of desirable acceptance rates.
6.3 Convergence diagnostics
Convergence diagnostics are designed to  assess how long to  run a Markov Chain 
in order to obtain reliable observations from the stationary distribution.
Gelfand et al. (1990) broached the subject with w hat is now known as their 
Thick pen technique. This requires running a Markov chain m  times, each of 
length t. Density estimates of the resulting distributions are drawn. For fixed ra, 
the authors increase t  and overlay plots of the resulting density estimates. If they 
coincide to  within a thick pen’s width then they can be said to  have converged 
by time t. For example, Figure 6-2 shows the resulting density estim ates from 
running a Markov chain from different starting values. Despite including any 
burn-in period, this plot shows good agreement of the estimates.
However, this is a time consuming and subjective exercise if the problem is 
other than  trivial and the authors therefore advocate the development of easily 
implemented autom ated diagnostics.
Opinion is divided over whether it is best to use one long chain or several short 
ones, both cases have merits and disadvantages. Some authors advocate running 
multiple chains, for example Gelman and Rubin (1992), whereas others prefer 
the use of single chains e.g. Heidelberger and Welch (1983), Raftery and Lewis 
(1992b). W hilst multiple chains have the benefit of using different starting 
points from which to assess convergence later on, single chains are said to be 
less vulnerable to initialisation bias (Heidelberger and Welch, 1983). Single run 
methods are also more efficient since a burn-in period is required only once and 
is hence less wasteful of computer time. The problem of how long to run the 
simulation is further complicated with multiple chains by having more than  one 
chain for which to  assess convergence.
There are now many autom ated convergence diagnostics which have been 
developed but none are really foolproof (Brooks & Roberts 1999a). Care must be
66
in o  -
0 5 10 15
thetab
Figure 6 -2 : Density estimates of the posterior distribution for 9b from chains with 
different starting points, drug= VO
taken as convergence may often be wrongly diagnosed (Roberts 1992). One of the 
problems of stationarity tests is the lack of power to detect an initial transient 
phase when the run length is shorter than tha t of the transient. However, despite 
their current shortcomings they are useful and a combination of both plots and 
diagnostics usually gives a good indication of convergence.
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6.4 CODA
Some of the more easily implementable and therefore popular convergence 
diagnostics are readily available in the package CODA. (Best et a i 1995). CODA 
consists of a set of functions which run within the S-Plus environment. It was 
originally conceived as an output processor for the BUGS software (Spiegelhalter 
et al. 1994) to assess convergence of the chains produced. On a practical note, 
since BUGS is not used to analyse this problem, output must conform to the 
specific format produced by BUGS in order to be able to  use CODA. The authors 
of CODA have implemented a range of convergence diagnostics in a convenient 
form, detailed below. We have used CODA to  test a variety of patien t/d rug  
combinations: to test all variables would be prohibitive given the more than 
2 ,0 0 0 , 0 0 0  analyses on the individual chains from each drug/patien t/variab le 
combination which would be required.
The examples given below illustrate the convergence diagnostics as implemented 
in CODA and refer the resultant chains from the drug=  V0 and patient =  70.
6.4.1 Graphical output
Figure 6-3 shows plots of the traces for the variables examined for drug=VO 
recorded for a particular patient together with the corresponding density 
estimates. Where variables are constrained to be positive, reflection (Silverman, 
1986) has been used when constructing these estimates. The traces appear 
to indicate th a t the chains have all reached their stationary distributions well 
within the burn-in period initially allowed despite the quite distinct starting 
values generated. All the traces show a rapid fluctuation about their stationary 
distribution indicating th a t the chains have been mixing well. The initial values 
and those generated during the burn-in period appear in the tails of the density 
estimates of the posterior distributions. These transient values have negligible 


























































0 2000 4000 6000 8000 1000C 
Trace of lambda
o
i 0 2 4 6 8 





0 2000 4000 6000 8000 10000
o
I 0 50 100 150 200 250 300
Trace of mux Q
Kernel density for mux
1I_________________________________________________ OJoo / \
0 2000 4000 6000 8000 1000C
o
i 0 1 2  3






0 2000 4000 6000 8000 10000 
Trace of thetab
o 1
i 0.0 0.5 1.0 1.5 





0 2000 4000 6000 8000 10000 
Trace of thetalambda
o
i 0 5 10 15 
Kernel density for thetalambda
I__________________________________________________ soo ZY
0 2000 4000 6000 8000 10000 
Trace of xstar
o
i 0 20 40 60 80 100 120 







0 2000 4000 6000 8000 10000 ° 0.0 0.5 1.0 1.5 2.0 2.5 3.0
Iteration Variable
Figure 6-3: Traces of variables for Drug=V0, patient=70.
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6.4.2 Geweke’s convergence diagnostic
Geweke (1992) proposes a diagnostic using tim e series methods. Given the 
sequence { G ( j) , j  = 1 , 2 ,...} , say, a comparison of values early in the sequence 
with those late in the sequence is likely to reveal failure of convergence. In order 
to perform this comparison we need an estim ate of the variance.
The method employs standard techniques from Spectral Analysis in order to gain 
variance estimates via the spectral density, S (u ).
The spectral representation of a stationary process, { G (t) ,t  =  0 , ± 1 ,...} , 
essentially decomposes (G (t)}  into a sum of sinusoidal components with 
uncorrelated random coefficients (Brockwell & Davies, 1991). In conjunction 
with this decomposition there is a corresponding decomposition into sinusoids of 
the autocovariance function 7 (k) of {G (t)}.
W here the derivative, dF(cj), exists, we obtain the Spectral Density function 
S (u )  so th a t
The autocovariance function can thus be re-expressed as:
/»7T
7 (k) =  / co s(uk)S (u )du .
The variance function thus is a special case of the autocovariance function when
7 (k) = E {[G (t) -  fi(t)][G(t + k) -  n (t + k)]}
Putting  k = 0 we then have:
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the lag k  =  0 (Chatfield, 1989). The autocovariance function and the spectral 
density function are equivalent ways of describing a stationary stochastic process, 
they contain the same information expressed in different ways.
The spectral density function is given as:
S{u) = 2 1 +  2 ^  pk cos(27ruk)
k= 1
where pk is the autocorrelation at lag k  and u  is the frequency.
In practice a smoothed version is used since the estim ated sample spectrum 
fluctuates wildly about the theoretical spectrum  and is inconsistent as the series 
length increases (Green h  Han 1999). This is given by:
S (u )  =  2
N - 1
7 (0) +  2 E Afc7 (&) c o s (27ruk)
k= 1
(6 .1)
where 7 (k) is the estimated autocovariance at lag k  and the Ak are suitably chosen 
weights called a lag window. The Ak decrease to 0 as k —>■ ± 0 0 .
The sample spectrum, Equation 6.1, is the Fourier cosine transform ation of the 
estim ate of the autocovariance function (Box et al., 1994)
The integrated autocorrelation time is simply 2n times the normalised spectral 
density function evaluated at frequency u  =  0, (Priestly, 1981, C hapter 4). The 
normalised spectral density function is simply given as
/ »  =
crG
The asymptotic variance for g = ^  1 G (j) ls giyen as the spectral density at
frequency 0 : S c (0 )/n .
Having obtained a formula to calculate an estim ate of the variance, the 
convergence diagnostic is calculated by dividing the chain into two portions 
consisting of the first 10% and last 50% after discarding a burn-in phase and 
then performing a comparison.
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We can now calculate Geweke’s convergence diagnostic as follows. Let
Pa h  Pb
^ £ G(j) and ^  =  ^ G{ i )
3 = 1  J —P
where (p* =  p — p s  + 1 ) . Also let 5^(0) and S q (0) denote the consistent spectral 
estimates for { G ( j ) , j  —  1, . . . , P a }  and { G ( j) , j  =  1, . . . , P b }  respectively.
The asymptotic variance of g£ is p _ 15^(0), similarly for g^. Geweke (1992) 
reports calculating 5g(0) using a Daniell window of w idth 27r/M, w hereM  = 
(0.3p 1/2).
Thus, we can derive an expression for the asymptotic standard  error for the 
difference of the means and hence obtain the test statistic  Z:
As the length of the chain n —> oo, the sampling distribution of Z  —> 7V(0,1) if 
the chain has converged. Large values of Z  indicate th a t the chain has not fully 
converged early on.
CO DA output for the Geweke convergence diagnostic
Table 6.2 shows the output produced by CODA. There is evidence to show th a t 
all chains apart from th a t for b have converged within the 1 0 , 0 0 0  iterations used 
since the Z-scores are reasonably small. However, the Z-score for b is fairly 
borderline using traditional cut-off values and running this diagnostic on the same 
patien t/d rug  combination with different starting values yielded slightly different 
results and this time b yields a Z-score of —1.28 suggesting there is not a serious 
problem with convergence here.
This diagnostic appears to yield somewhat erratic results when tested on different 
portions of the same chain. Running the same chain for 50,000 iterations and
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GEWEKE CONVERGENCE DIAGNOSTIC (Z-SCORE):
Iterations used = 1001:10000 
Thinning interval = 1 
Sample size per chain = 9000
Fraction in 1st window = 0.1 
Fraction in 2nd window = 0.5









+  +  +
Table 6 .2 : CODA output fo r  Geweke convergence diagnostic.
testing for convergence after every 10,000 iterations gives the Z-scores in Table 6.3. 
Convergence is diagnosed differently dependent on the length of the segment 
examined, the Z-score varying substantially. Each chain segment has had at 
least one variable deemed to have “failed” the convergence test.
One documented disadvantage of Geweke’s diagnostic is its sensitivity to the 
specification of the spectral window (Cowles & Carlin, 1996). The spectral 
window is essentially a weight function expressing the contribution of the spectral 
density function to the expectation of S (u )  (Chatfield, 1989). Also, intuitively, 
one would expect th a t using a longer chain would increase the chances of 
convergence begin diagnosed, however, with large samples, results of hypothesis 
tests are often significant even when the effects are quite small (Chatfield, 1988, 
C hapter 7). As with all hypothesis testing, multiple tests increases the risk of a 
Type I error and the results from this diagnostic test must be used cautiously.
6.4.3 Gelman and Rubin convergence diagnostic
The diagnostic proposed by Gelman and Rubin (1992) is a m ethod based on 
running more than  one parallel chain, each started  from different over-dispersed 
starting  values with respect to the stationary distribution. M ultimodal target
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Number of Iterations 
Variable 1 0 , 0 0 0  2 0 , 0 0 0  30,000 40,000 50,000
b -1.99 - 1 . 8 8 0.52 -3.29 -2.42
A 0.47 -0 . 2 0 -1.36 -0.33 -0.33
fj>x* 0.73 -0.32 -2.04 -1.71 -1.28
-1.24 1.25 1.57 2.25 1.89
9b -0 . 2 1 -2.38 -1.28 -1.24 -1.16
dx -1.33 0.70 0.52 -1.31 -1.56
X* -1.59 1.58 -1.05 -0 . 6 6 1 . 1 1
Table 6.3: Z-scores from  the Geweke convergence diagnostic from  different sized 
chain portions.
distributions can give iterative simulation algorithms serious problems because 
the chains may take a long time to move from the region of one mode to  another 
and may not be long enough to make these moves. Running several chains can 
reduce this risk of not visiting all modes of the distribution. This approach also 
provides useful information about how well the chains are mixing by comparing 
characteristics from each chain produced. However, this m ethod runs the risk of 
spending too long in such extreme modes with respect to  the target distribution 
and results may be biased if the chain is run for a sufficiently long time.
The technique is based on a comparison of the within-chain and between-chain 
variances for each variable, similar to  an analysis of variance.
This diagnostic involves running m >  2  sequences each of length 2 n  and having 
different starting  points. The m ethod disregards the first n  iterations and uses 
only the last n. For any scalar function of interest 9(x), convergence is monitored 
by estim ating the factor by which the scale of the posterior distribution for 6 
shrinks as n  increases and the early over-dispersion is lost.
The estim ated shrink factor, R , is given as:
/ /  n  — 1 m  + 1 B \  d f
Y \  n m n  W J  d f— 2 ’
where B  is the sample variance between means of the m  chains, W  is the average 
of the m  within chain variances, and d f is the degrees of freedom.
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G ELM A N  A N D  R U B IN  5 0 %  A ND 9 7 . 5 %  S H R IN K  F A C T O R S :
Iterations used for diagnostic = 5001:10000
Thinning interval = 1




Point est. 97.5% quantile |
11
1 b 1.01
- - 1 
1.03
| lambda 1.01 1.05
| mux 1.00 1.00
| sigma2x 1.00 1.01
| thetab 1.00 1.00





Table 6.4: CODA output for Gelman and Rubin convergence diagnostic.
The factor computed will eventually decline to 1 as n —> oo and the measure of 
convergence is the closeness of the estimated factor to 1. However, the authors 
give no indication of how close to 1 the shrink factor needs to be to be considered 
satisfactory.
C O D A  o u tp u t  for th e  G e lm an  & R u b in  convergence  d iag n o stic :
CODA reports the median and 97.5% quantiles of the sampling distribution for 
the scale parameter by which the marginal posterior distribution may be reduced 
if the chain were run to infinity. If the shrink factors for both these quantiles are 
close to 1.0, it may be inferred that effective convergence has occurred and the 
samples may be assumed to have arisen from the stationary distribution.
In Table 6.4 all the values are fairly close to 1 and we can conclude that there 
is no evidence that the chains have not converged. The plots in Figure 6-4 show 
that for all variables the median and 97.5% quantile for the shrink factors, except 
6, have stabilised to around 1.0 well before the first 1000 iterations. The slope 
variable b takes a little longer but the associated shrink factors are satisfactory. 
Despite the aforementioned problems associated with using multiple chains, this 
diagnostic yields consistent results when applied to different chains and thus 
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Figure 6-4: Graphs showing Gelman & Rubin Shrink Factors.
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6.4.4 Raftery and Lewis convergence diagnostic
Raftery and Lewis (1992b) consider the problem of calculating the number of 
iterations necessary to estimate a posterior quantile from a single run of a Markov 
chain. For some function 9 of a param eter (or set of param eters) X , we wish to 
estim ate from the data  the value, u , such th a t
P (6{X ) < u ) = q
for some stated  value q so th a t the P( 6( X)  < u) lies with ± r  of the true value 
with probability p. The method involves first calculating the length of the burn- 
in period and secondly the number of further iterations, n, required to  estimate 
the probability to within the required accuracy. They also suggest thinning the 
the chain by storing only every sth iteration. The estim ated number of iterations 
required for the desired accuracy actually increases when estim ating quantiles 
nearer to  the median compared to  more extreme quantiles. If these quantiles 
are not of interest, this method must be used with caution (Brooks & Roberts, 
1999a). In another paper, Brooks & Roberts (1999b) go on to  suggest th a t rate 
of convergence is consistently overestimated and hence the suggested burn-in 
lengths are underestim ated. They recommend using the m ethod for a number of 
quantiles and to  take the largest burn-in length, although if quantiles themselves 
are not of interest this method should not be relied upon to  provide definitive 
answers.
CO DA output for the R aftery and Lewis convergence diagnostic:
The output as given in Table 6.5 for precision ±0.01 and probability of 97.5% 
shows the param eters required in order to  obtain accurate estimates of the 2.5% 
quantile. If the samples in the chain were independent, then N m in  would be the 
minimum number of iterations required. Since the samples are not independent, 
the final column showing the dependence factor, we need to  take a longer run 
length and then thin the chains by the factor shown in the first column. Thinning 
the chains reduces the autocorrelation but can been seen as wasteful. The higher 
the dependence factor, the more iterations are required. However, since we are
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RAFTERY AND LEWIS CONVERGENCE DIAGNOSTIC:
Iterations used = 1:10000 
Thinning interval = 1 
Sample size per chain = 20000
Quantile = 0.025 














1 b 7 49 12208 937
OJ1
| lambda 2 72 19362 937 14.5 |
| mux 2 16 4230 937 5.2 |
| sigma2x 1 13 3574 937 3.9 |
j  thetab 1 21 5846 937 0.5 j
| thetalambda 1 18 4789 937 4.9 j
| xstar 1 21 5632 937 6.9 j
+  +  +
Table 6.5: CODA output fo r  Raftery and Lewis convergence diagnostic.
most interested in the LC90 and the output recommends taking all values for X*, 
this does not affect the validity of our results. It can be seen th a t both b and A 
need to run by longer than  the run length given to  achieve the specified accuracy 
with the desired probability. By relaxing these param eters to  those given in the 
CODA manual (0 . 0 2  and 0.9 respectively) the run length now required ranges 
from a minimum of 640 for cr%* to a maximum of 3470 for A which is less than  
the 1 0 , 0 0 0  iterations th a t we used.
Critics of this method point out th a t the technique can produce variable estimates 
of the required number of iterations given different initial values for the same 
problem (Cowles & Carlin, 1996): applying this diagnostic to the same problem 
with different starting values yields wildly different results in the estimated 
recommended run length for b, see Table 6 .6 (a) and compare the values obtained 
with those in Table 6.5. The associated value for N  is now given as over
400,000, although the other variables have recommended run lengths well within 
the number of iterations actually used. Reducing the initial accuracy to  ± 0 . 0 2  
reduces these values approximately fourfold (Table 6 .6 (b)). However, when we 




(a)1 0 , 0 0 0
± 0 . 0 1
(b)1 0 , 0 0 0
± 0 . 0 2
(c)2 0 , 0 0 0














b 1681 468,823 1681 116,467 159 10539
A 38 9471 38 2397 56 3656
Px* 13 3584 13 906 13 904
1 1 3045 1 1 770 1 2 821
0 6 33 9021 33 2280 18 1225
0A 17 4516 17 1142 16 1079
X , 2 1 5797 2 1 1465 30 2052
Table 6 .6 : Raftery & Lewis diagnostic fo r  differing accuracies and run-lengths
dram atically to  marginally over 10,000. The N  for other variables also changes 
but their direction is not consistent, see Table 6 .6 (c).
Another criticism of using this method to determine run length is th a t sub­
sampling from a chain produces a poorer estim ate than  when using the full 
chain. MacEachern & Berliner (1994) prove this and advise th a t thinning chains 
is inappropriate in most cases. Sub-sampling in this case is used to  simplify the 
calculation of the diagnostic.
6.4.5 Heidelberger and W elch’s convergence diagnostic
The method of Heidelberger and Welch (1983) is concerned with identifying 
transient phases in simulated sequences of discrete events using Brownian bridge 
theory. If we have a sequence (T ( j) ,  j  = 1,..., n )  from a stationary process with 
spectral density p( f )  , let
n
So = 0, S n =  Y , Y U ) ,  n >  1
F = H E m
3 =1
Bn(t) =  ^[ni] ~  j^ Q)) ’ 0 -  t  ~  1»
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where [nt\ indicates the greatest integer <  nt. Then B n =  {B n(t)7 0 <  t  <  1} 
converges in distribution to the Brownian bridge B  =  {B (t) , 0 <  t < 1 } as 
n —v oo. So for large n, B n is distributed approximately as the Brownian bridge 
B . The null hypothesis th a t the sampled values for a given variable form a 
stationary process is tested using the Cramer-von-Mises statistic:
•l
\2 .f  B n{ t fd t  = C Y U {B n). 
Jo
This statistic has a known asymptotic distribution under stationarity  and is 
sensitive to the existence of an initial transient. As n —> oo it converges in 
distribution to: r i
B i t f d t  =  CVM(B).
L
In practice, since p(0), the spectral density a t zero frequency is unknown, the 
approximation
_  S[„t] -  [nt]Y 
(np{ 0 ) ) 1
is used instead.
If the null hypothesis is rejected, the first 1 0 % of iterations are discarded. The 
process is repeated until either the the chain passes the stationarity  test or 50% 
of the iterations have been discarded.
The authors of this diagnostic found th a t the stationarity  test had little power 
to  detect an initial transient when the run length was shorter than  the extent of 
the initial transient.
CO DA output for the H eidelberger and W elch convergence diagnostic:
The output produced by CODA in Table 6.7 reports the number of iterations 
to  keep for each variable, i.e. those which are diagnosed to  have arisen from 
a stationary process if the stationarity  test has been passed. The halfwidth is 
calculated to be 1.96 x asymptotic standard error: if it is less than  e times the 
sample mean (where e is a small fraction), then the retained sample is deemed 
to  estim ate the posterior mean with acceptable precision.
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H E ID E L B E R G E R  A N D  W E L C H  S T A T I O N A R I T Y  A N D  I N T E R V A L  H A L F W ID T H  T E S T S :
Iterations used = 1001:10000 
Thinning interval = 1 
Sample size per chain = 9000
Chain: vo
+ ------------------------------------+ ----------------------------------------------------------------------------------------------------------------------------+
| | Stationarity # of iters. # of iters C-vonM |
Variable | test
I
to keep to discard stat.
b
1
| passed 10000 0 0.314
lambda | passed 8000 2000 0.454
mux | passed 9000 1000 0.129
sigma2x | passed 9000 1000 0.194
thetab | passed 7000 3000 0.378
thetalambda | passed 9000 1000 0.385
xstar | passed 9000 1000 0.098
| Halfwidth 1
Variable | test Mean Halfwidth |
b | passed 3.28
l
0.049 |
lambda | passed 228.0 1.330 |
mux | passed 0.32 0.004 |
sigma2x | passed 0.48 0.005 |
thetab | passed 8.42 0.869 |
thetalambda | passed 32.7 0.122 |
xstar | passed 1.21 0.007 |
Table 6.7: CODA output fo r  Heidelberger and Welch convergence diagnostic.
All the variables in our example pass both  the stationarity  test and the halfwidth 
test. However, it suggests discarding more than  the initial burn-in period allowed 
for both  A and Oj,.
6.4.6 Correlations
High cross correlations amongst param eters are associated with slow convergence 
and may indicate the need for re-param eterisation of the model (Best et al., 1995). 
The cross-correlation m atrix for the chosen example is shown in Table 6 .8 . All 
the values are fairly low showing no obvious problems.
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Variable b A o't* 0b Ox x*
b 1 . 0 0 0
A -0.063 1 . 0 0 0
fj>x* -0.017 0.024 1 . 0 0 0
-0.048 -0.005 0.005 1 . 0 0 0
eh 0.035 -0.013 -0.029 -0.038 1 . 0 0 0
0 . 0 0 2 0.024 -0.027 0.007 -0.025 1 . 0 0 0
X* -0.419 -0.277 0.0516 0 . 0 2 2 0 . 0 0 1 -0.048 1.000
Table 6 .8 : Table o f cross correlations
A utocorrelations
Autocorrelations measure the corrrelation between observations a t different 
distances apart, k where k = 1 ...N  — 1 . They can be useful in indicating the 
rate  of convergence in a chain. Although short term  correlation is to be expected 
even for a stationary chain this will get successively smaller for greater values of 
k. High long term  correlations within chains indicate slow mixing and, usually, 
slow convergence. This is characterised by plots of traces which move slowly as 
opposed to showing more rapid fluctuations over the sample space. Very low 
or very high acceptance rates lead to highly correlated samples. One way of 
compensating for this is to thin the chain by taking every n th observation and 
discarding the rest, however this has been shown to reduce the accuracy and so is 
rather wasteful. Muller (1993) suggests a  scheme for monitoring the acceptance 
rates within the chain over the last 1 0  iterations and rescaling the size of jumps 
possible by ± 2 0 %. This would not be appropriate for the discrete variables in 
this problem and the values proposed are very subjective with no account given 
of their suitability.
6.4.7 Summary of convergence diagnostics
As stated  previously, no convergence diagnostic is foolproof and some can give 
varying results depending on which segment of the chain we look at, the run 
length used and the starting values used. Table 6.9 gives a summary of whether 
each technique diagnosed convergence or otherwise for the illustrated example.
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Gelman k Raftery k  Lewis Heidelberger k
Variable Geweke Rubin (a) (b) Welch
b borderline yes borderline yes yes
X yes yes no yes yes
l^ x* yes yes yes yes yes
yes yes yes yes yes
eb yes yes yes yes yes
yes yes yes yes yes
X* yes yes yes yes yes
Table 6=9: Comparison of convergence diagnostics
The methods of both Geweke and Raftery k  Lewis can give inconsistent results. 
Geweke’s diagnostic appears to be over-sensitive and large run lengths appear to 
exacerbate the problem; this may be from underestim ating the variance used 
to  compute the Z-score. Raftery k  Lewis’s technique also varies depending 
on the chain length used, the same problem can yield very different answers 
using different starting points. The methods of Gelman k  Rubin appear 
to yield consistent results although their interpretation is subjective and not 
straightforward.
W hilst these diagnostics are useful, they cannot be wholly relied on without 
further evidence of convergence or otherwise. A plot of the chain is often the most 
useful tool: although convergence is assessed visually, this is usually sufficient. 
The motivation behind autom ated convergence diagnostics appears to  have been 
partly  to remove the subjective element and speed. However, many techniques 
are slow even when autom ated and param eter choices still have to be made.
Having performed these diagnostic tests on a variety of d rug/patien t 
combinations, we are satisfied th a t the chains do converge within the length of 
burn in used, and often much before this. We are also satisfied with the run length 
of 1 0 , 0 0 0  iterations to yield reliable estimates. As we are especially interested in 
the posterior distribution of the LC90 and it passes all the diagnostic tests, its 




Running the programs for each drug produces a wealth of information, of which 
the LC90 is the variable in which we are most interested and the most im portant 
from the view of the medical practitioner.
From the output of our analysis, we can learn much about each drug’s behaviour 
from the output produced and how it can vary between different patients, drugs 
and tum our types. This information can be re-used to produce estimates of a 
new subject’s LC90 from new assays without running the model using the whole 
dataset again, which can be very time consuming.
7.1 Chapter outline
We shall examine the results produced in a number of ways, a summary of which 
is given below:
•  S e c tio n  7.2 P o p u la t io n  p a ra m e te rs :  This section deals with the main 
variables and how they differ between drugs.
•  S e c tio n s  7.3 a n d  7 .4 In d iv id u a l d ru g s : The results from two drugs, 
ACD and IFN, are examined in detail here. The former is an example of 
a typically behaved drug and the la tter is a drug for which it has been
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difficult to obtain reliable estimates.
•  S e c tio n  7.5: This section looks a t the results for separate patients and 
how to interpret them.
•  S e c tio n  7.6 F u tu re  su b je c ts : The problem of how to analyse additional 
patients whose results were not included in the main analysis is looked at 
in this section.
7.2 Population parameters
A summary of the three main variables for each drug is given in Table 7.1. W hilst 
the underlying rate of cells per slide, A d o e s  not differ greatly between drugs, 
the slope, bi, and log10 LC90, x* do as the drugs all behave in very different ways 
and the estim ated dose response curves reflect this.
Since A^ does not depend on the drug behaviour, its variability between drugs 
is much reduced as, although this not a randomised study, the patients have not 
been allocated to assay drugs purely by tum our type or other systematic criteria 
related to the number of cells expected if left untreated. The average slope of the 
drug response curve varies from just over 2 to nearly 9, dem onstrating differing 
changes in rates of survival versus log10 dose. The variability of slopes between 
patients within each drug is large, see, for example, Figure 7-1 which shows all 
dose response curves for one drug and illustrates this variation. The estimated 
log10 LC90s also show considerable variation both  within and between drugs 
which can also be seen in Figure 7-1.
These results can be further broken down into the different tum our sample types. 
Figure 7-2 shows the estim ated log10 LC90s according to the type of tum our. For 
viewing purposes, the vertical axis on the graph has been sorted according to the 
log10 LC90s for CLL tum our samples. The pattern  clearly emerging shows the 
solid tum our clumps are the least responsive to  nearly all drugs apart from PR, 
MAF and ASP. CLL is the most responsive sample type in approximately 75% 
of cases.
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Drug Number of Patients Mean(A) sd(A) Mean (b) sd(6 ) Mean(x*) sd(x*)
ACD 258 67.17 53.71 4.21 1.55 -0.99 0.91
ACL 245 71.23 50.37 7.43 1.97 -0.41 0.67
AMS 504 70.09 56.41 3.70 1.82 -0.51 1.36
AR 661 75.50 58.42 3.61 1.73 0.91 1.08
ASP 328 77.51 61.46 2 . 1 2 1.62 2.43 1.18
BC 297 63.62 53.70 7.38 2.17 1.61 0 . 6 6
BL 517 69.96 53.85 2.93 1.38 2.36 0.95
BU 155 71.96 58.26 3.65 1.58 2 . 6 6 0.89
CB 594 70.78 56.51 6.61 1.87 1 . 6 6 0.58
CC 465 71.03 57.79 7.15 2 . 1 0 1.44 0.67
CCA 169 79.89 59.81 2.91 1.37 1.80 0.98
CDA 876 83.29 57.50 3.77 1.58 -0.97 0.97
CHL 1048 80.35 59.39 5.49 1 . 8 6 0.74 0.80
CP 482 6 6 . 1 0 57.36 6.28 1.77 0.85 0.61
DC 720 83.87 58.07 1.55 1.41 1.80 1.31
DEX 369 72.83 54.16 2.03 1.57 2 . 0 0 1.19
DN 416 78.81 60.10 6.32 1.95 -0.65 0.71
DOX 1147 74.07 57.64 5.81 1.72 -0.44 0.79
EPI 1 0 0 2 79.97 58.23 6.69 1.78 -0.38 0.71
FL 1052 81.53 59.73 3.88 1.51 -0 . 0 2 0.92
FU 331 53.93 48.75 3.61 1.62 2.27 0.89
GLA 1 1 1 71.96 66.93 5.50 2.42 3.39 0.91
HIF 553 70.68 57.25 8.90 2.17 0.81 0.74
HN 105 62.63 46.77 5.18 1.80 0.27 0.72
HU 189 65.92 54.50 4.83 2 . 0 1 3.25 0.74
IDA 432 73.27 59.40 5.42 1.79 -0.83 0.77
IFN 1 1 1 55.00 53.13 5.50 2.42 3.39 0.91
LP 514 70.94 59.29 5.09 1.81 0.82 0.76
MAF 1070 72.65 56.13 6.39 1.94 0.55 0.81
MEP 370 77.68 55.53 2.64 1.80 1.43 1.07
MMC 846 59.95 48.31 4.92 1 . 6 8 0.13 0.76
MP 406 76.07 59.09 4.29 1.87 2 . 8 8 0.84
MZN 545 71.50 57.62 4.98 1.99 -0.46 0.85
PR 975 76.31 57.18 2.51 1.74 1.94 1.06
TAX 63 65.78 48.28 5.55 1.87 2 . 1 1 0.80
TG 421 77.93 65.43 3.97 1.52 1.74 0.78
VB 417 67.55 54.68 4.06 1.81 0.70 0.95
VC 915 73.83 56.12 2.54 1.52 0.51 1.04
VD 254 67.43 59.34 3.21 1.65 1.05 1 . 0 1
VM 103 65.75 63.14 5.08 1.85 0.38 0.79
VO 84 65.01 50.82 3.21 1.54 0.31 0.81
VP 664 68.98 56.13 4.39 1.73 1.40 0.85
Table 7.1: Posterior means and standard deviations o f A, b and x* fo r all drugs 
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Figure 7-1: .Dose response curves for ACD showing all Solid samples.
The overall trend in order of responsiveness is: CLL, Leukaemias & and
Lymphonas, Normal, Solid tumours and Solid clumps. For many drugs, cell 
survival rates of solid tumours and solid clumps remained high a t even the highest 
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Figure 7-2: log 10LC90s for all drugs sorted by CLL results.
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Figure 7-3: Sorted \ogloLC90s for A CD with 95% estimates.
7.3  In d iv id u a l drug: A C D
We shall examine the drug, ACD, initially. The estimated mean LC90s are shown 
in Figure 7-3 with corresponding 95% posterior intervals for each patient using 
the log10 Dose scale. From this graph, we can see th a t there are 3 patients with 
very wide intervals, patient numbers=67, 152, and 181. On further inspection, 
the latter two patients have very low cell densities on the control slide (1.3 and 
0 . 1  respectively), and the remaining one has only one valid value for Yijk, the 
category of surviving cells. Both of these factors lead to imprecise estimates. 
W ith such small control values, a change in the estimated number of surviving 
cells, riijk, of just 1 cell, results in a large change in the proportion of surviving 
cells, which then gives wildly fluctuating LC90s. The lack of data  for patient 67 
yields a chain which has few constraints and moves about freely, again resulting 
in a very spread posterior distribution for the LC90.
Of more practical use to the clinician involved in selecting the drugs for treatm ent 
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Figure 7-4: Sorted LC90 Ranks for ACD with 5% and 95% percentiles. 
both drugs and patients.
The percentiles are calculated by ranking the current LC90 of each patient from 
1 after each iteration of the MCMC algorithm, where p is the number of 
patients with assays for a particular drug. When the run has been completed 
the median rank achieved by each patient is noted, similarly for the 5% and 95% 
points which then give a 90% posterior interval for the rank of the patient’s LC90 
within all the other patients in the analysis. These results are then re-scaled from
1,..., 100 for ease of interpretation, see Figure 7-4.
Presenting results in this way is more natural for clinicians who can then report 
whether a patient is likely to respond well if their LC90 is in the top 10% say, of 
responses to that drug when compared to the other patients. This information 
can then be used in order to help prescribe a treatment using the indicated 
drugs or a combination of them. It must be noted, however, that a good relative 
response to a particular drug does not necessarily mean the patient will respond 
favourably. Some drugs may only be effective for a small proportion of cases,
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and the dose required to achieve the LC90 for the next best response may be 
too toxic to  tolerate despite having relatively high percentiles for the LC90. The 
percentiles must be used in conjunction with the estim ated LC90 in order to 
ascertain the relative merits of particular drugs.
The use of percentiles however allows us to compare the relative merits of other 
drugs in order to  get a comparison of potential response.
7.3.1 Dose response for ACD
We assumed the cell survival to have a logit relationship with dose since no 
cells were killed a t zero dose and all cells were killed a t a sufficiently large 
concentration. The model provides us with estimates for the slope of the dose 
response curve and also the log10 LC90 which gives us the location.
Figures 7-5 to  7-8 show the fitted dose response curves for single patients (patient 
numbers 15, 3, 69 and 179). These patients have been chosen to highlight some 
of the characteristics of the responses and also to  show some unusual behaviour. 
On the graphs the vertical bars represent the recorded range of surviving cells; 
they have been staggered slightly for viewing purposes. There are up to 4 bars 
per dose depending how many sets of results were recorded and whether any of 
these values are missing. It is impossible to  represent category 8  accurately as 
this is open ended and represents all cell survival rates over 60%. W here there are 
fewer cells on the control slides than the treated slides, the estim ated proportion 
surviving may thus exceed 1 0 0 %, we have therefore constrained the maximum 
range depicted to be 1 2 0 % cell survival: this is only for pictorial convenience and 
the program has no such constraint.
To obtain the fitted cell survival curves we use the posterior mean of the log10 
LC90, x j, for the location of the curve and the posterior mean of bi for the slope.
Figure 7-5 is a typical response curve with a comparatively steep slope (6 1 5  =  7.5) 
and the LC90 being achieved between doses 3 and 4. It also shows the ^ 15,3 ,^  
values are discordant at dose level 3: the curve reflects this by passing between the 
categories. The other doses have good agreement for the cell survival categories
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Figure 7-5: ACD Dose response curve for Patient 15, drug=ACD
with them all having the same recorded categories apart from dose 2  which 
differs by just 1 adjacent overlapping category, since one scientist was consistently 
recording lower values than the other.
The dose response curve for Patient 69 is shown in Figure 7-6. This patient 
has only two sets of results which differ widely for the two largest doses. The 
estimated log10 LC90 is 2.32, which is larger than the range of doses tested. The 
ranks achieved for this result range between 99-100% indicating a poor response 
is likely if this drug were used.
Figure 7-7 shows a patient (number=3) with a very sensitive ex vivo result. The 
estimated LC90 of 0.00229 /xg/ml is achieved at a lower dose than any of the 
other patients. During the ranking process, the corresponding LC90 percentiles 
are 0-3% indicating tha t the result is reliable and the drug has a good chance of 
being effective.
Figure 7-8 shows the flattest dose response curve seen for this drug. The recorded 
categories do not agree well. One replicate actually shows an increase in the
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Figure 7-6: ACD Dose response curve for Patient 69, drug=ACD  
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Figure 7-7: ACD Dose response curve for Patient 3, drug=ACD
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Figure 7-8: ACD Dose response curve for Patient 179, drug=ACD
proportion of cells surviving with dose. The fitted curve reflects this with a 
shallow gradient and an LC90 which is ranked between 94-98% in the patient 
population.
Although plotted on the same scale, these figures show a different range of doses 
used in the assays between the first two and latter two graphs. The latter graphs 
are in fact earlier assays and a maximum concentration of 50/zg/ml was used. 
In assays performed later on, this was changed to 5//g/ml since the LC90 had 
been already been achieved at lower concentrations so the range of doses used 
was focused on a smaller area. The dilution factor remained the same regardless 
of the maximum concentration used.
Figure 7-9 shows all dose response curves for the drug ACD, broken down 
by tum our sample type. These graphs show steep slopes to be a common 
characteristic with slope gradients less then 1 occurring in only 6  of the 258 
patients. The figure also reveals solid tumours to have far a more varied response 
curves and hence estimated LC90s than the other sample types. This variability
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Figure 7-9: ACD Dose response curves for all patients by tumour type
may be due in part to many of these assays having smaller control values since 
cells are harder to distinguish and sometimes “clumps” are counted rather than 
individual cells, often leading to a very small nO^, reflected by low values for A* 
(Table 7.2).
The summary of the other im portant posterior distributions, broken down by 
tum our type, is shown in Table 7.2. Both the Solids and Solid Clump samples 
have lower underlying numbers of cells A;; they also show higher variability in 
slope, bi and log10LC90, x \.  Their estimated LC90s are higher than other sample 
types showing a possible worse prognosis for Solid and SC tumours when treated 
with ACD.
In general, both slope and LC90, and hence the cell survival curves, vary 
considerably over all samples. This reflects the initial problem of choosing a 
drug for an individual patient since, even with the same disease type, patients 
respond very differently.










Leukaemia Sz Lymphonas -1.385 0.579 4.221 1.891 81.19 57.53
Normal -1.053 0.348 4.093 2.062 88.36 61.20
Solid -0.372 1 . 0 1 1 4.286 3.162 33.05 26.00
Solid Clumps -0.311 0.871 3.982 3.092 40.15 29.83
CLL -1.561 0.541 4.673 1.930 67.95 42.89
Table 7.2: Posterior means and standard deviations fo r  ACD.
achieved the LC90 within the dose ranges tested. The least precise estimates are 
derived from patients with very little da ta  or very small control values.
7.4 Drug IFN
In contrast to  ACD, we shall also examine IFN as an example of a drug with 
d a ta  for which it has proved hard to obtain reliable estimates. Less than  10% 
of patients were assessed to have an LC90 within the range of doses tested: 0.4 
-  102.4 /ig/m l, (-0.39 -  2.02 on the log10 scale). Many assays show no recorded 
decrease in cell survival with increasing dose. Figures 7-10 and 7-11 show the 
plots of the LC90s with corresponding posterior intervals and the ranks achieved 
during the simulations.
Both plots reveal a few results with small confidence regions a t a lower dose and 
the m ajority of patients with imprecise estimates a t higher doses.
One patient has an uncharacteristically large posterior interval even though the 
LC90 is achieved a t a relatively low dose (Patient 111). The reason for this is 
a very flat dose response curve, with slope bm  =  0 . 8  owing to  missing d a ta  as 
well as recorded categories actually increasing with dose for one replicate, see 
Figure 7-12.
Figure 7-13 shows all dose response curves by disease type. They are very different 
from the drug ACL (Figure 7-9). There is a wide variety of both  slope and 
location within all sample types. Many curves have very low gradients; these 
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Figure 7-11: Sorted LC90 Ranks for IFN with 5% and 95% percentiles.
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Figure 7-12: Dose response curve for IFN patient 111.
occasionally increases have been recorded which further distort the curve.
If the range of doses tested had been sufficiently broad to actually contain the 
LC90, the results would be more accurate. However, such high doses may not be 
tolerated by patients and more accurate estimates at such high levels could be 
impracticable to prescribe safely.
7.5  In d iv id u a l p a tien t resu lts
We shall look at the results of individual patients in order to examine the 
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Figure 7-13: IFN  Dose response curves for all patients by tumour type. 
7.5.1 P a tien t num ber 1765
Table 7.3 shows all the assay results from patient number 1765. Of the 26 sets of 
results, there is a wide variety in slope between drugs which ranges from 0.5 to 
nearly 13. The log10LC90 also shows considerable variation.
The drug showing the “best” assay result in terms of the lowest estimated 
log10LC90 is MEP with a value of -1.252. The corresponding 5, 50 and 95 
percentiles of ranks achieved are 0 , 2 , and 7. The next smallest estimated 
log10LC90 is CDA with -1.23: the corresponding ranks however are 40, 50, and 60. 
Thus the absolute values do not always agree well with their relative positions. 
This is to be expected as some drugs work well at lower doses and some require 
high doses to be effective.
The estimated dose response curves are shown in Figure 7-14. Whilst most drugs 
tested on this patient have curves with steep slopes, there are five drugs with very 




5% 50% 95% b
AMS -0.859 23 28 37 0.76
AR -0.281 6 1 1 19 1.96
ASP 2.887 48 58 75 1.23
BC 1.076 7 1 1 17 6.70
BL 2.135 35 42 49 2 . 1 2
CB 1.743 49 59 69 7.55
CC 1.127 15 23 39 4.20
CDA -1.232 40 50 60 2.64
CHL 0.401 28 33 39 4.20
DC 3.905 79 91 97 0.54
DN -0.890 23 29 35 12.14
DOX -0.96 1 2 15 2 2 7.21
EPI -0.583 24 34 41 12.34
FL -0.261 38 44 52 3.15
HIF 0.086 7 9 14 7.58
IDA -0.987 37 43 47 1 0 . 2 1
LP 0.364 16 2 1 28 3.70
MAF -0.032 1 2 19 27 12.81
MEP -1.252 0 2 7 0.56
MP 2.60 2 1 27 39 9.27
MZN -0.710 27 31 36 6.38
PR -0.546 1 4 9 0.59
TG 1.929 55 64 72 3.38
VB -1.06 1 4 9 0.82
VC -1.082 3 8 15 0.63
VP 1.322 40 47 54 5.88
Table 7.3: Assay results from  one patient (No=1765).
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Figure 7-14: Dose response curves for all assays performed for Patient 1765.
tested (MEP and PR), two the vincal alkaloids used (VB and VC) and AMS is 
one of the two antibiotics examined (the other antibiotic, BL, has a steep curve). 
Both the vincal alkaloids and steroids have their median LC90 percentiles within 
the top 10% whereas AMS is ranked in the 28th percentile.
Of the drugs tested for this patient, there is a range in their relative 
responsiveness. Drugs with their median LC90 rank in the top 10% are HIF, 
MEP, PR, VB, and VC. Their posterior intervals are sufficiently narrow to provide 
confidence in these choices. There are also drugs showing a poor relative response, 
the least effective of these being DC which is in the bottom  1 0 % of potential 
responders.
7.5.2 P a tien t num ber 1306
Table 7.4 shows the assay results from a patient with a poor response to nearly 
all the drugs tested. Again there is a wide variety in the estimated slopes of the
1 0 1
drug response curves, although these are much steeper than  the previous example 
ranging from 2  to  over 25. There is only one drug which indicates the patient may 
be in the top 50% of responders, FU, whereas all the others have poor predicted 
responses.
Figure 7-15 shows all the response curves for patient 1306, which have a similar 
shape over a range of locations. Ranking of this pa tien t’s LC90 with the whole 
population tested is highest for FU. The dose response curve for FU is not 
obviously any better than the other drugs tested in Figure 7-15 as it does not have 
a particularly small LC90 when compared on the same scale as the other drugs. 
However, the other results show lower percentile rankings so the decision to treat 
with FU will depend on whether the dose can be tolerated in vivo. Also the 
relative benefits of the other drugs tested may show lower estim ated LC90s will 
depend on the overall efficacy of the drug, a lower percentile may not necessarily 
mean a worse response. It is especially im portant in cases like these th a t we 
are confident the type of assay used has a good clinical correlation i.e. a strong 
relationship between ex vivo sensitivity and actual response.
7.5.3 Patient number 1383
In contrast to patient 1306, patient 1383 has a very good response to  the drugs 
tested. The figures are shown in Table 7.5. Although fewer drugs are tested 4 
have their median values to be within the top 1 0 %.
Figure 7-16 shows a variety of response curves, however they all show fairly steep 
curves and the LC90s have all been estim ated within the doses tested.
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Drug log10LC90 Percentile ranks 
5% 50% 95%
b
ACD 1.197 95 97 99 14.59
ACL 1.591 98 99 1 0 0 16.24
AMS 1.466 96 98 1 0 0 1 0 . 8 8
AR 3.042 87 92 98 7.26
ASP 2.905 41 55 8 8 6.40
BC 3.220 98 1 0 0 1 0 0 6.47
BL 2.727 61 6 6 72 6.70
BU 3.368 52 77 97 8.64
CB 2.133 84 94 98 24.62
CC 3.036 97 99 1 0 0 7.04
CDA 1.087 91 95 99 7.264
CHL 1.671 89 92 96 10.59
CP 1.587 97 98 99 7.51
DC 3.047 60 72 89 4.01
DEX 4.156 8 8 95 1 0 0 6.03
DN 0.393 96 97 98 9.44
DOX 0.487 90 93 94 11.26
EPI 0.425 92 95 96 6 . 8 6
FL 1.627 94 95 96 6 . 8 6
FU 2.053 34 40 48 6 . 0 0
GLA 3.557 2 0 52 92 10.13
HIF 2.928 99 1 0 0 1 0 0 8.47
HU 4.379 94 97 99 2.19
IDA 0.928 99 1 0 0 1 0 0 3.20
IFN 3.557 2 0 52 92 10.13
LP 1.924 95 97 99 10.42
MAF 2.461 95 99 1 0 0 14.36
MEP 2.835 81 92 98 13.70
MMC 0.711 77 87 93 2.69
MP 4.347 85 96 1 0 0 2.25
MZN 1.151 96 97 99 7.80
PR 3.726 99 99 1 0 0 25.68
TG 2.390 82 89 94 3.61
VB 1.920 8 6 90 96 9.61
VC 2.813 95 98 1 0 0 7.45
VD 2.420 72 89 98 9.32
VO 1.430 93 95 98 8.56
VP 3.146 93 97 1 0 0 8.06
Table 7.4: Assay results from  one patient (No=1306.)
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Figure 7-15: Dose response curves for all assays performed for Patient 1306. The 
estimated curve for FU the drug with the highest percentile result is highlighted 
in bold.
Drug log10LC90 Percentile ranks 
5% 50% 95%
b
BL 0.422 0 1 3 6.70
CC 1.199 17 32 47 7.04
CCA 0.994 8 17 37 7.04
CDA -2.563 0 1 5 7.264
CHL 0.116 8 17 37 10.59
DOX -0.951 9 16 27 11.26
EPI -0.818 6 1 2 25 6 . 8 6
FL -1.448 0 3 1 2 6 . 8 6
MAF -0.296 3 7 14 14.36
MEP 1.792 47 55 63 13.70
PR 2.162 41 50 61 2.69
VC -0.288 18 23 30 2.25
Table 7.5: Assay results from one patient (No=1383).
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Figure 7-16: Dose response curves for all assays performed for Patient 1383.
7 .6  F u tu re su b je c ts
The results reported so far are from the analysis of complete sets of data  gathered 
over a number of years. When further assays are performed on a new subject, 
we could add these into the existing data  sets and run the full analyses again for 
each drug tested, processing data for previous patients again as well as tha t for 
the new patient. The main disadvantages in doing this are:
• A big calculation is involved again, a lot of which is unnecessary.
•  The people performing the assays and collecting the data  a t the hospital 
would prefer to have a smaller program which is quicker to run and requires 
less maintenance.
It is a feature of Bayesian updating tha t data can be processed in batches and 
population parameter distributions updated with each new set of data. The 
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Figure 7-17: Directed Acyclic Graph of model for extra subjects.
the particular problem of analysing assay results for a new case after a large 
historical set of data. In order to analyse the new case, it is sufficient to know 
the posterior joint distribution of A, 6 , and x*\ the initial cell density, slope and 
LC90 respectively, for a new subject. We have therefore obtained these posterior 
joint distributions for each drug and cell type combination.
7.6.1 New m odel param eters
Figure 7-17 shows the existing model modified to accept information about 
posterior distributions from the initial analyses which is in turn  used as prior 
information for the less complicated model required for just one extra case. The 
historical analysis in this figure only shows the im portant variables from which
106
information is utilised in the second model. For the complete diagram of the first 
model, see Figure 4-6.
From our initial analysis, the instinctive approach would be to  build up a posterior 
distribution of 0\,K x,9b ,^b^x*  and a%*, and use this to  define a sampling 
distribution y ( 9 \ , 9 b ,
Another technique to obtain the sampling distribution would be to  include a 
“new patient” as an extra case in the model and keep updating y{9\,9b, px*) for 
this case and then model its posterior distribution. However, this method has 
smaller variation in the posterior distributions for the variables we are interested 
in since it is considering just one “typical” patient. The between patient variation 
is considerably larger than  the within patient variation for all variables and thus 
we would underestim ate the overall expected variation.
The m ethod employed has utilised the posterior distributions obtained from A, 6 , 
and x*. We can fit standard distributions to these variables by deriving estimates 
for the distribution param eters from the relevant posterior distributions. We now 
use these in place of the original hyperpriors (9x, 9b, Kb, Hx* and o^*).
This m ethod has the advantage of not being tied to the same distribution as 
specified in the initial prior model where we specified diffuse prior distributions.
7.6.2 Deriving prior distributions
In order to use the posterior distributions obtained from the initial analyses as 
prior distributions for analysing new subjects, we must find some way of fitting 
suitable distributions which describe them  adequately. Firstly we need to  check 
whether the variables can be considered as independent.
We shall take the drug ACD as an example. To test independence, we can 
draw scatter plots as in Figure 7-18. The points represent the posterior means 
for the main variables A, 6 , and x* taken from all patients regardless of sample 
type. Using these graphs we can perform visual checks for whether there are any 
discernible trends: the plots in this case all look unrelated. A further check is 






0 50 100 150 200 250 300
X*







0 2 64 8 10 12 14
8
o
•2 0 21 1




0 50  100 150 200 2 50  300
Figure 7-18: Matrix of scatter plots for ACD.
show either negligible correlation or are sufficiently small to cause no concern. 
Hence there is no evidence of any demonstrable relationship between these 
variables and so they can be considered independent for subsequent purposes.
We can now model the distribution of A, 6 , and x* which we shall use as prior 
distributions for the parameters of a new subject. Since both A and b are required 
to be positive, as our starting point we use Gamma(0, k) distribution, with 
m ean= 0 K and variance=#2 /c.
As x* is on the log10 Dose scale, negative values are perm itted and so a Normal 
distribution can be used as a prior distribution taking the posterior mean and 
variance as its parameters.
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B A X *
B  1 -0.053 0.143
A -0.53 1 -0.043
X* 0.143 -0.043 1
Table 7.6: Correlation matrix fo r  the posterior distributions, Drug=ACD.
A table has been constructed which contains all the posterior means and standard 
deviations of 6 , A and x* for all drug and tum our cell combinations so th a t new 
prior distribution param eters can be evaluated. See for example Table 7.2; the 
values vary considerably between disease type for each drug as well as across 
drugs. Posterior distribution summaries of the initial hyper-prior variables are 
not given since new hyper-prior variables have new param eters calculated from 
the posterior distributions of their offspring.
To check th a t the distributions chosen for the priors are appropriate, we can use 
graphical methods. To assess the goodness of fit, we can overlay the theoretical 
density functions on the posterior distribution histograms. For example we look 
a t the drug ACD. Figure 7-19 shows the fitted distribution as a dotted line. In 
all cases the fits seem satisfactory. A further check is to use qq plots, as in 
Figure 7-20. A perfect fit would show all points to lie on the diagonal. Any 
systematic deviation from this indicates a poor fit: slight departures, especially 
a t the extremities are to be expected. O ther drugs show broadly similar results. 
However since these fitted distributions are used to provide prior information, 
the subsequent analyses are fairly robust to the actual prior distribution used, it 
is not necessary to obtain perfect fits.
W hilst it may initially seem th a t shrinkage may occur in deriving new param eter 
estimates from A, b, and x* rather than  simply using the posterior distributions of 
the 0\, 6b, p>x* and cr%*, this is not actually the case. The estim ated variance for x* 
from the posterior of this variable is either larger or of a very similar magnitude 
when compared to the estimate derived from the posterior distribution of <7 ^*. 
The estim ated variances of both A and b are consistently larger when using the 
relevant posterior distributions to derive these values rather than  those from the 
respective hyperprior posterior distribution.
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Figure 7-19: Histograms and fitted distribution for drug=ACD.
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within patient variation. Using information which takes into account the posterior 
distributions of all patients rather than  merely a distribution param eter of this 
posterior distribution gives a similar or bigger variation.
In order to estim ate any future subjects, we require the following information: 
the control values, the proportions of surviving cells and the dose levels used. 
Together with the drug and tum our type, the param eters for the new prior 
distributions can be estimated.
7.6.3 Analysing a new case
We define 7r0 (A, b,x*) as the posterior distribution of A, b, x* for one new 
subject following the analysis of the complete historical data. The new posterior 
distribution of (A, 6 , x*) given y  can now be evaluated:
_ q  a r n  = __________ M \b ,x * ) l{ y ,X ,b ,x * )______________ , .
f x, f r  f x.' no(X ',b ',x ,')l(y;X',b',x*')dX'db'dx*'
where 7To is the new prior distribution derived from the previous posterior 
distribution and /(.) is the likelihood of the observed data.
The integral can be evaluated numerically using, for example, Simpson’s rule. If 
the problem had been of a higher dimension, this approach would not perhaps 
be possible and running further models using the MCMC approach adopted 
previously may have been more appropriate.
A program has been provided to the RUH by Jennison which uses the posterior 
distributions of (A,b,x*) obtained from the main analyses and estimates these 
param eters for the additional case by evaluating Equation 7.1 above.
This new method of analysing additional cases has allowed us to investigate the 
m ethod of d a ta  collection and to propose new strategies. In the historical data  
analyses, categories were of varying widths depending on whether the surviving 
proportions were large or small. They also overlapped by often considerable 
margins. There is scope for making precise counts of cells when there is a low 
underlying count (control value) or when numbers of surviving cells are small.
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We have found th a t it is relatively efficient to “guesstimate” when the cell 
survival rate  is high but exact counts are desirable otherwise since this reduces 
the scope for error. In consultation with the scientists a t the RUH involved in the 
performing the assays and evaluating the results, this has led to  a new protocol 
in cell counting. Obviously time is a factor, so exact counts are only made when 
numbers are sufficiently low for this to  still be an efficient way of determining 
survival proportions.
7.6.4 U pdating posterior distributions
It would be nice to keep on updating the posterior joint distribution of (A, 6 , x*) 
as more subjects are analysed. However, this is not so easy to  implement and 
not too critical if there is sufficient historical da ta  so the posterior distribution of 
(A,b ,x*) really does reflect the population distribution accurately, i.e. with little 
extra variability due to uncertainty about the actual population distribution.
We can check the future results are consistent with the historical sample by 
looking a t the combined posterior distribution of all the new cases. A more time 
consuming way would be to run the MCMC of the initial model with all the new 
d a ta  added and see how this affects the posterior distributions first obtained.
W ithout sufficient da ta  this is impossible to check satisfactorily bu t performing 
analyses on just part of the da ta  show a good agreement where there is sufficient 
da ta  to  start. W ith sufficient further data, we can investigate how large an 
initial sample is required before there is no appreciable increase in accuracy of 
the estimates.
7.7 Conclusions
The value of performing these assays and obtaining accurate estimates of the 
LC90 is dem onstrated by showing the variability of cell survival curves both 
between drugs and sample types. It is impossible to predict in advance whether 
a patient will respond well to some drugs and not others. The DiSC assay used for
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these studies shows a clinical correlation of 84% according to Bird et al. (1988) 
indicating th a t it is a good prognostic indicator of actual clinical response as well 
as a means of providing information on the sensitivity of a tum our to specific 
drugs. We can thus be confident th a t the results obtained here provide a very 
useful basis for prescribing treatm ent.
Analysing all the historical da ta  means we are able to  use the posterior 
distributions obtained as prior distributions when analysing new cases. This 
gives a real benefit in terms of efficiency as there is a smaller model to consider 




We have already seen th a t the recorded categories for the proportions of surviving 
cells often differ between replicate slides or between counters. This may be due 
either to the actual differences in the numbers of cells between the two sets of 
slides or to  the different assessment of live and dead cells between the scientists. 
W hen the slides are stained, the dye makes the live cells appear m agenta under 
the microscope whereas the dead cells show up black. However, there are many 
dying cells which fall between these colours and it is often not clear cut how 
these should be categorised. This choice is therefore necessarily subjective and 
can lead to  substantially different assessments of the proportions of surviving 
cells especially when the cells are sparse. We wish to have some idea of how these 
discrepancies may affect the results obtained and whether such discrepancies have 
much effect on the estim ated LC90s.
8.1 Outlier definition
B arnett and Lewis (1978) define an outlier to  be an observation (or subset of 
observations) which appears to be inconsistent with the remainder of th a t set 
of data. Outliers in this problem include both those which initially appear 
discordant with the rest of the data  values and values which subsequently deviate 
substantially from fitted model.
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Young and P e ttit (1996) consider ways of measuring discordancy between the 
d a ta  and the assumed prior in order to  test for the presence of outliers and also 
the adequacy of the model. After seeing the data  they use Bayes factors to  check 
whether the prior elicited from an expert (in our case, the scientists a t the RUH) 
is misguided and th a t the data  do not conform to their expectations. However, 
they concentrate on discordancy between the prior and d a ta  using Bayes factors, 
we are more interested in how our posterior fits the data.
There are two basic mechanisms which give rise to  apparent outliers (Hawkins, 
1980). The first arises when the data  come from some heavy tailed distribution 
such as a ^-distribution. The second involves two distributions: a basic
distribution which generates well behaved observations and a “contam inating” 
distribution which generates “contam inants” . The tendency is for extreme 
observations to come from the la tter distribution.
8.2 Bayesian approach to  outliers
If a model is to be believed, the posterior distribution allows all relevant 
estim ation inferences to be made about its param eters (Box, 1980). Thus, 
while individual values may appear inconsistent with the model, these are not 
necessarily of importance and we look a t the influence these values may have.
B arnett and Lewis (1978) outline some Bayesian methods to  deal with outliers. 
Since such techniques require an a priori statem ent about the possible values 
of param eters in a param etric family of models, this must include a prior 
assessment of probabilities attached to the presence of outliers. Therefore we 
must anticipate the possible presence of outliers and structure our d a ta  generating 
model accordingly before analysis of any data.
It is generally agreed th a t it is desirable to accommodate possible outliers 
regardless of the mechanism assumed to give rise to them  e.g. Besag & Higdon 
(1999), B arnett h  Lewis (1978). Just as there are two mechanisms from which 
we assume outliers arise, there are two main ways of dealing with them. The first 
is to  ensure the prior distribution supports the possible occurrence of outliers by
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using non-informative or even improper priors, see, for example Young & P ettit 
(1996), the second assumes outliers arise from distributions other than  th a t of 
the specified prior, eg Kale & Sinha (1971).
Kale and Sinha (1971) propose a model in which n — k of the observations 
x i ,X 2, . . . ,x n arise from some basic population F  whilst the remaining k 
observations (the outliers) arise from populations G i, G2, ..., G* distinct from F .  
It is assumed th a t before recording the observations, there is no way of identifying 
the anomalous subset or its size, k. It is also assumed th a t any subset of size k 
of the n  observations is equally likely to be the set of observations arising from 
G i, G 2 , G f c .
This is term ed the exchangeable model since we assume th a t joint distribution of 
the random variables ( X i ,  X 2, ... ,  X n ) is the same as th a t of ( X j 1 , X j 2, ..., X j 3 )  for 
all perm utations j n) of (1 , 2 ,. . . ,n ) .
This is in keeping with de F ine tti’s (1961) theory of exchangeability and his 
argument th a t any approach to outliers be couched in such terms.
This type of approach requires alternative distributions to be specified yet this is 
difficult to do since often we do not know an appropriate alternative since we have 
little information about the outliers. Young & P e ttit (1996) use Bayes factors to 
compare the discordancy of different prior models and can then proceed to select 
the models with the least discordant priors.
Box (1980) states th a t each model under consideration can be imagined as being 
embedded in a more complex one. The model is the prior in the wide sense th a t 
it is a probability statem ent of all the assumptions currently to be tentatively 
entertained a priori. We write our model as
P ( y D , 0 \ A )  =  m y D , A ) ? ( y D \ A )
where y n  is the observation being examined, 6  is the vector param eters, and A  
represents the conditionality assumptions made in the model.
We can partition yn  into y* and yw  where y* is the outlier in question and y&
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is the rest of the data so we now have:
P(3/*, VD',  e\A) =  P (% *, yD,, A ) P ( y * \ y D ., A ) P(yD, |4).
The second factor:
P ( V , \ V D ' , A )  =  J  P(y'\yD',e ,A)P{e\A)d9
is the predictive density associated with the value y *  actually obtained. If the y *  
was unlikely to  be generated by the model, this could be assessed by reference 
to  the density P(T|^4) or of the density { g i ( y * \ A ) }  of some relevant checking 
function g i { y * ) .  In making this check, it is not necessary to be specific about an 
alternative model.
Gelfand et al. (1992) consider outliers and residuals as way of assessing model 
adequacy. They note Box (1980) states th a t the posterior distribution provides 
a basis for estimation  of param eters conditional on the adequacy of the model 
whilst the predictive distribution enables criticism  of the model in the light of 
the current data. They proceed to explain th a t in model comparison predictive 
distributions are directly comparable whilst posteriors are not. The predictive 
distribution (or marginal likelihood) is the joint marginal of the data  and may 
be used for model determination.
The predictive distributions f{ Y r \y(r)) are to be checked against yr for r = 1, 2 , ...n 
so th a t if the model holds, yT may be viewed as a random observation from 
f ( Y r \y(r))i where Y  denotes a n  x 1 d a ta  vector, yr is the r th value from 
our sample w ith ?/(r) the (n — 1 ) x 1 vector w ith observation r om itted. To 
assess the model adequacy, Box (1980) advocates the use of a checking function, 
g(Yr \yr), whose expectation under f ( Y r \yr) is calculated and denoted by dr. The 
strategy employed is a Bayesian analogue to  the frequentist version of examining 
studentised residuals. Several choices for g are available to  us but all have the 
characteristic th a t many large |dr | cast doubt upon the model.
Standard Bayesian methods for model choice given J  proposed models M j  
denoted as f ( Y \6 j \X ,  Mj)7r(9i) also makes use of the predictive distribution.
118
Let Wj denote the prior probability of M j . Using Bayes Theorem, the posterior 
probability of M j is:
j
piMjlY) = }{Y\Mj)wj/ Y Jf{y\Mj)wj (8.1)
3=1
where f (Y \M j)  is the predictive or joint marginal distribution of the da ta  under 
model M j .  For observed data, y, the model yielding the largest p ( M j \ y )  is 
selected.
Gelfand et al. (1992) suggest this approach is impractical and unrealistic and 
proffer a maximum expected utility approach which modifies this basic idea. An 
alternative form is to choose M i if :
‘ n  f ( Y r \y{r),M i)
og n / ( y r |y(r),A f2)J >  0 (8 .2)
where f*  = W iU f(Yr \y ^ ,  M i)  -f- W2l l f ( Y r \y(r), M 2). If this condition is not 
satisfied, model M 2 is chosen.
This expected utility approach is readily extended to J  > 2  models.
The approach of Besag and Higdon (1999) towards the assessment of outliers 
involves substituting the Gaussian distribution usually assumed for residuals by 
a contam inated Gaussian one with heavier tails such as the Student’s tVy where 
vy itself has a prior distribution. They call this a hierarchical ^-formulation with 
the prior for i/y to be uniform on (1, 2, 4, 8 , 16, 32, 64) although of course any 
other choice could be made.
Realistically, model criticism is often conducted by visual inspection of residual 
displays designed to highlight “features” in the da ta  th a t would rarely be extreme 
if the model were true. If such a feature can be described by a function g i ( y * ) ,  
its unusualness, if formalised, would be measured approximately by reference to
P{ft(v*|A)}.
The distinction between param etric features of the model and residual features 
is somewhat arbitrary. In practice the needs of parsimony urge us to  settle for
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reasonably simple models and to consider possible deviations from them.
Of the two main types of approaches outlined for dealing with outliers, the first, 
requiring specification of alternative prior distributions from which outliers are 
said to belong, is too cumbersome to  be used in this particular problem. The 
approach of Box (1980) is more appropriate in th a t no alternative distributions 
are required. This is especially relevant given the non-standard distributions with 
which we are mainly concerned.
8.3 Outlier detection
Detection of outliers can be very subjective if we do not know a priori the likely 
patterns of outlying values of the variables. In this problem we are concerned 
th a t several of the y-values do not “fit” with the rest of the observations and we 
wish to  assess the impact of these atypical values. Such da ta  can be referred back 
to  the scientists who counted the cells, who can re-examine the slide and possibly 
provide new counts, or, if the slide is found to be of poor quality, simply remove 
the relevant da ta  points.
8.3.1 Initial screening
In order to  detect possible outliers we must first devise some algorithm for 
identifying them  automatically. Given the size and nature of the d a ta  set being 
examined it would be impractical any other way. It is also less subjective and far 
more efficient since algorithms can be incorporated into the existing programs.
Figure 8 - 1  shows the different probabilities of being in each category according 
to  the actual proportion of surviving cells. Most values may fall in one of two 
categories since these categories overlap, often substantially. The lower categories 
are much narrower where more care is taken to ensure accurate counts are taken 
when cell survival is low.
Thus we define observations which differ by more than  one category to be 
discordant. If a recorded observation is observed to be discordant with all the
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Figure 8-1: Probability of being in recorded category given proportion of surviving 
cell.
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Figure 8-2: Drug ACD, Patient 4• Proportions of surviving cells.
1 2 1
other y  values we flag it as a possible outlier. For example, see Figure 8-2; 
whilst the 4 higher doses all agree, the smallest dose has three values of Y  at 
category 5 (15-45%), the final replicate has a recorded value of 7 (45-100%). If 
an observation is found to be discordant, we take this as an indication it should be 
analysed more closely with a view to declaring it as “outlier” and either removing 
it from the analysis or referring it back to the scientists for re-assessment.
Obviously we need more than  2  sets of replicates to determine this as otherwise it 
is impossible to  say which of two observations is the more unlikely without further 
d a ta  being available. Therefore only subjects with a t least three replicates are 
considered in this manner.
A nother type of outlier in this type of da ta  may occur when the recorded 
categories are decreasing non-monotonically and the value does not appear to 
fit with the rest of the data. An example of this is shown in Figure 8-3. In 
this case it is harder to detect which value is likely to be an outlier, the fourth 
or fifth value as this would depend on the slope of the dose response curve. If 
further replicates were available, then this may help with the identification of the 
erroneous value.
8.3.2 Formal assessm ent of outliers
In assessing a value flagged as a possible outlier we exclude the observed value 
from our analysis ju st as we would trea t a missing da ta  value. In the MCMC 
analysis, new values are proposed for the “missing” observation and accepted or 
rejected according to the probabilities given in Section 5.6.2. In this way we can 
look at the resulting distribution of values for this observation generated in our 
Markov chain and compare this distribution with the value actually recorded. 
We then have some information of how inconsistent the recorded value is when 
compared to  predictions based on the rest of the data. If the recorded value is 
inconsistent with these predictions we declare the observation as an outlier. This 
approach departs from a strict application of de F ine tti’s model as we have not 
specified just how we expect observations to behave when they do not follow the 
standard model: although such a specification might be possible in priniciple, it
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Figure 8-3: Drug IFN, Patient 48. Proportions of surviving cells.
is not clear how one should start to create one and we are happy to sidestep this 
issue in our treatm ent (Box, 1980).
8 .4  R e su lts
We shall use the drug ACD to illustrate the methods and typical results achieved. 
Of the 258 patients with ACD assays, 47 had sufficiently discrepant values 
recorded to result in possible outliers being flagged. These values were treated 
as missing and the model as described in Chapter 4 was run again so we can 
compare the sets of results.
The drug ACD is “well behaved” in tha t the recorded survival proportions (Yijk) 
are all non-increasing with increasing dose in all but one assay (Patient 32). As 
mentioned in Section 8.3.1 the second type of outlier is harder to detect as it 
depends on the neighbouring observations and the underlying model. We shall 
use the drug IFN as an example of an “ill behaved” drug with survival proportions
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Dose: log10 p g /m l 0.0005 0.005 0.05 0.5 5
Replicate 1 Slide 1 Counter 1 5 1 1 1 1
2 Counter 2 5 1 1 1 1
3 Slide 2 Counter 1 5 1 1 1 1
4 Counter 2 7 1 1 1 1
Table 8.1: Drug ACD, patient 4'- Recorded Y  values (categories fo r  proportion of 
surviving cells).
actually increasing with drug dose. The presence of discrepant values does not 
generally alter the LC90 estimates. However, if a marked proportion are affected 
significantly, this also affects the associated rankings which may change by several 
percentile points.
The first record we encounter with a potential outlier for the drug ACD is patient
4.
A C D , P atient 4
In this case, the value flagged as discrepant is replicate 4, a t the lowest dose level. 
The recorded category is 7 (45% - 100%) as opposed to the other three recorded 
values of 5 (15%-45%), see Table 8.1. The resulting Markov Chain when treating 
this value as missing yields the posterior distribution as shown in Figure 8-4.
The posterior mode is 5 which agrees with the other values recorded. This is 
achieved 46.3% of the time whereas the actual value recorded, 7, is visited only 
1.7%.
Table 8.2 shows the estim ated param eter values for both  using the value as 
recorded and treating it as missing.
The estimates for X *, the log10LC90 do not alter much, nor do the associated 
rankings. However the slope, B , is much lower with a much reduced standard 
deviation indicating a more reliable estimate, see Figure 8-5 to see how this affects 
the estim ated dose response curve. This is to be expected since the estimated 
Y value is now the same as the other replicates for nearly 50% of the updates
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Figure 8-4: Drug ACD:Posterior distribution for Y+^i.
E(X*) sdX*) E (B) sd(J3)
Ranks 
5 50 95
Initial Estimate -1.93 0.113 5.01 1.49 7 10 16
New Estimate -1.98 0.103 3.59 0.78 6 9 13
Table 8.2: Drug ACD, Patient 4- Parameter estimates both before and after 
omission of potential outlier.
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Figure 8-5: Drug ACD, Patient 4■ Proportions of surviving cells.
performed. It is worth noting that the control value, the underlying cell density 
for an untreated slide, for the patient is 113 and any changes in the number of 
surviving cells will not drastically alter the survival proportions and consequently 
the LC90s. This particular example shows little difference in the LC90 and so, 
although the recorded value may be regarded as atypical, being visited less than 
2 % of the time, there is little overall effect to concern ourselves about.
We shall look at further examples of where the control value is small and this 
does have a bearing on the estimated LC90.
A C D , P a t ie n t  48
The next example we shall consider is patient 48, also the ACD assay. Table 8.3 
shows the recorded values. The possible outlier here is replicate 1 , dose level 3. 
The control value recorded for this assay is 36.3, which is relatively small.
Figure 8 - 6  shows the posterior distribution achieved after running the model. It
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Dose: log10/zp/ml 0.0005 0.005 0.05 0.5 5
Replicate 1 Slide 1 Counter 1 8 7 7 1 1
2 Counter 2 8 7 4 1 1
3 Slide 2 Counter 1 8 7 5 1 1
4 Counter 2 8 7 4 1 1
Table 8.3: Drug ACD , patient 48: Recorded Y  values (categories fo r  proportion 
of surviving cells).
Ranks
__________________E(X*) sdX*) E(B)  sd (B)  5 50 95
Initial Estim ate -0.98 0.126 2.29 0.40 62 72 79
New Estim ate -1.13 0.114 2.80 0.53 36 49 60
Table 8.4: Drug ACD , Patient 48. Parameter estimates both before and after 
omission o f potential outlier.
can be seen th a t the recorded value was visited 0.003% of the tim e and the mode 
was 4, with 54.3% of the time spent a t this value. This agrees well with the other 
recorded values.
The corresponding param eter estimates are given in Table 8.4. In this case, 
treating the potential outlier as missing does have an affect on the LC90. 
Bringing this atypical value to  resemble the other replicates reduces the LC90 
somewhat from -0.98 to -1.13 on the log10 scale. The corresponding ranks change 
considerably so they do not overlap. The initial median rank is 72, and the new 
one is 49, although this does have a slightly bigger range.
As previously stated, this patient has a relatively small control value so small 
differences in assessing the cell survival rates do greatly affect the LC90, as can 
been seen in this case.
IFN , P atient 48
This example shows a case where the proportions of surviving cells show an 
increase with dose, the last recorded value being greater than  the previous 
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Figure 8 -6 : Drug ACD .Posterior distribution for >48,1,3 .
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Figure 8-7: Drug ACD, Patient 48. Proportions of surviving cells.
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Figure 8-8: Drug IFN, Patient 48. Fitted Survival Curves.
the actual dose response curve we cannot say which of the values for doses 4 and 
5 has the greater residual. We use the term residual in a general sense since we 
cannot calculate exact values not having precise data. When we plot the initial 
dose response curve in Figure 8-8, the initial estimated curve, shown by the solid 
line indicates it is value for dose 4 which appears to be atypical so it is this value 
we omit from our second analysis.
The dotted line in this Figure (8-8) shows a dose response curve above the original 
which is to be expected. The estimated proportion of surviving cells at this dose 
is 0.44 which is represented on the graph by the point.
The corresponding numerical estimates show a reduction in variation for both 
slope and LC90. The estimated LC90 has increased slightly with the related 
percentiles showing an increase in the median but a smaller overall range.
When we examine the posterior distribution of Kts.i,4 , as depicted in Figure 8-9, 
we note th a t the recorded value only appear in 1.48% of the simulations.
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Figure 8-9: Drug IFN, Patient 48. Posterior distribution for  148,1,4-
E(X*) sdX*) E (B) sd (B)
Ranks 
5 50 95
Initial Estimate 2.97 0.735 1.26 0.52 11 28 80
New Estimate 3.23 0.599 1.25 0.43 14 31 60
Table 8.5: Drug IFN, Patient 48• Parameter estimates both before and after 
omission of potential outlier.
Spotting this type of potential outlier before we run the initial analysis is harder 
as this will depend on the underlying dose response curve which we do not know. 
Whilst the data  indicate there may be a problem, it does not readily indicate 
which of the values does not fit with the model beforehand.
8.5  C o n c lu sio n s
Existing literature concentrates on assessing the discordancy of the data  from the 
prior whereas we are more concerned with the posterior. W hilst two main schools
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of thought exist over whether to  consider outliers to come from distributions other 
than  th a t of the main data  or to  assume a heavier tailed distribution, in practice 
we tend towards more simple parsimonious models. We try  to explain why outliers 
may happen and in this problem it may be one of several reasons: a simple mis- 
recording of the data, an assay has failed to  work correctly, differences in the cell 
survival assessment and a very small control value which can lead to  inaccurate 
d a ta  as there may be no “typical” areas of the slides to examine. Another simple 
explanation could be th a t the recording categories overlap more than  stated  and 
have longer tails than  the simplistic tent shaped probability function as depicted 
in Figure 8-1 which we have used as our prior.
We have looked at some typical examples here where the treatm ent of potential 
outliers has differing effects. If the control value is small, the LC90 may differ 
considerably when simulated. A larger control value leads to a more robust 
estimate.
In nearly all cases where there has been a reduction in estim ated slope, there has 
also been a reduction in the associated posterior standard deviation. Where the 
initial analysis had given a high slope and standard deviation the new estimate 
has both  a lower slope and a far smaller standard deviation.
If a value is flagged as a potential outlier because it disagrees with the other 
recorded values, it is useful to be able to  check whether this value has been 
recorded properly and if not perhaps to  perform a recount of surviving cells if 
possible. As with all outliers, this may be a genuine observation bu t may be due 
to some undiscovered problem with the assay procedure.
However, we are confident th a t these values do not have an im portant effect on 
the estim ation of the LC90s as long as there is a sufficiently large control value 
to  ensure an accurate estimate. If the control value is small, we have imprecise 
estimates regardless of the presence or absence of outliers. If the estim ated LC90 
has a large associated error due to small control values then om itting these rogue 
values and re-estimating the model will often yield a more precise estimate.
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Chapter 9
Conclusions and Further Work
9.1 Clinical implication
We have met our initial aims in providing an autom ated mechanism which gives 
reliable estimates for the LC90.
We can produce efficient estimates of the LC90 for each assay performed for each 
patient and drug combination. This is accompanied by an associated measure of 
accuracy which is indicative of the reliability of this estimate. However, what the 
program is unable to do is indicate whether a drug will be effective in vivo, but 
it does give relative rankings with respect to all the other assays performed for 
each drug. The decision whether to use a particular drug ultim ately depends on 
clinical judgem ent but more detailed information is now available to the clinician 
which enables a better decision to be made. Since it is impossible to  give each 
drug to  every patient to check the ex vivo results against in vivo responses, the 
results from the assays aid the determ ination of a potentially effective treatm ent 
or treatm ent combination and vastly reduces the chance of non-efficacious drugs 
being chosen.
As well as providing estimates of the LC90 and dose response curve, we have 
summarised the information by drug and tum our type. In providing the mean 
and posterior intervals for our variables of interest, we can assess the potential 
efficacy of subsequent assays w ithout having to  run a long analysis each time.
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In the analysis of this da ta  it can be seen th a t the inter-drug and inter-patient 
variation, as expected, is great. Although patients with good responses in some 
drugs will often tend to have favourable results across all assays, this does not 
mean th a t poor responders in some drugs will not respond to  any drugs.
For some drugs there is less information available initially and as assays continue 
to  be performed, we can utilise this additional da ta  in two ways: firstly as model 
check by comparing the original analysis with subsequent results and secondly 
incorporate the additional da ta  to improve the accuracy of results.
The benefits over the original method of curve fitting and manually reading off the 
LC90 from the resultant graph are manifold. There is a significant time saving 
in analysing all drug types together which also makes use of the information 
from each patient. The analysis also takes into account the ranges of values 
each recorded category represents whereas the graph fitting ju st used the mid 
points. We are able to give an idea of the accuracy of our estimates using 
the posterior distributions obtained which was impossible using the initial graph 
fitting methods.
This assay based approach to  treatm ent, whereby a range of drugs is tested ex 
vivo for potential patient sensitivity in vivo, can be used in other areas of cancer 
treatm ent. Different assays method will be more appropriate for different tum our 
type, the DiSC assay used here did not perform as well on solid tum ours, however, 
the underlying principle is the same.
Further generalisations of these methods could extend to other types of diseases 
and drugs: wherever a drug induced resistance occurs, it is especially vital to 
identify an effective treatm ent as early as possible. Although these assays will 
not replace clinical trials, there is legislation governing the conduct, much can 
learned from them, especially when a drug is in its developmental stages.
Since cancers are notoriously difficult to  trea t effectively and much of the 
treatm ent available is highly toxic, new drugs are not tested on healthy volunteers 
as happens for many other drug types. Often anti-cancer drugs are treated in 
vivo on patients who have failed to respond to prior treatm ent and as such have 
poor prognoses. There are problems inherent in this approach not only because of
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the drug induced resistance from previous treatm ents which makes this particular 
group of patients even more difficult to t r e a t . However, this does give us a chance 
to  check clinical correlations and a response observed here is worth investigating 
thoroughly as it is harder to achieve.
Early indication of efficacy in a drug’s developmental stages is beneficial to  both 
the pharm aceutical industry and clinicians as it can prevent a waste of resources, 
as well as patients as these resources can be directed in areas of potential benefit 
earlier.
9.1.1 Assay counts
From the analysis of this data, we would like more accurate counts to  remove some 
of the inaccuracy which may be caused by very wide survival categories. Owing 
to  the labour intensive methods, it is not practical to  perform exact counts for 
every dose level. However, in light of the results from our analyses, the scientists 
a t the RUH are now performing actual counts where there are few cells, rather 
than  simply categorising the survival categories. At higher cell densities where 
an exact count is very time consuming, the estim ated cell survival is rounded to 
the nearest 5%. This does not appreciably increase the workload involved.
Also, since scientists can differ in their assessments, all sets of control values and 
counts are recorded.
It is too early to  tell how big an impact this will have in the estim ation of the 
LC90s but we are confident it will reduce some variation.
9.2 M odel review
We shall look at the model implemented and review the m ethods used and 
consider alternative methods th a t could also be implemented where appropriate.
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9.2.1 M odel specification
We are satisfied th a t the model in final use, as described in C hapter 4, is a good 
representation of the data  collection process. The inclusion of hyper priors for 
the param eters of the parent nodes’ prior distributions allows these variables 
more freedom and less dependence than  if a straightforward prior distribution 
had been specified. It is useful to be able to feed back information gleaned 
from the d a ta  by using fairly informative priors based on information given and 
scientific judgement rather than simply use non-informative or improper priors. 
Thus the prior distributions in use reflect any knowledge gained with respect to 
the variables of interest. O ther distributions could perhaps have been used as 
priors but we are satisfied the ones used give acceptable results and make use of 
the knowledge we have.
The distribution of the categories of surviving cells, as shown in Figure 8-1, 
could benefit from having a wider overlap between categories and longer tails 
in light of the subsequent results. This may reduce the possible problems of 
irreducibility as all values would then have some probability attached, however 
small, hence there would be no illegal or incompatible categories. The issue 
of irreducibility has been resolved in Chapter 6 with a careful identification of 
starting  values which are compatible with the da ta  and the probability model.
O ur choice of the “ten t”-like probability function used for the yijks was based on 
information given. We subsequently realised th a t these categories may not be as 
precise as originally thought owing to various factors: mainly the small numbers 
of underlying cells nOij.
We also make the assumption of a logistic relationship between log10 dose response 
and cell survival. We assume all cells survive a t zero dose and all cells are killed 
a t a sufficiently high dose. This gives us a convenient function as we have no 
further information about this survival curve. It could be th a t this function is not 
the most appropriate and th a t different drugs may have very dissimilar curves. 
Nevertheless, the assumption made seems not unreasonable in the absence of 
further data.
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9.2.2 M odel im plem entation
Although software is available which carries out MCMC analyses, for example 
we consider the use of BUGS (Spiegelhalter et a l, 1994), this is too slow for our 
needs and hence we develop our own programs. The development of our own 
software meant we can incorporate all the data  features required and tailor the 
m ethods chosen to  suit our own specific needs.
We chose the Metropolis Hastings algorithm to perform our updating steps since 
the distributions in use are not standard and hence not conjugate. We could 
perform Gibbs updates on some of the steps but in the interests of simplicity we 
have used the same method throughout.
The calculations for the acceptance probabilities have been carefully coded to 
try  and ensure efficiency since some operations are more “expensive” in term s of 
com puter resources than  others.
9.2.3 M odel convergence and validation
We need to ensure convergence in order to  use our results with confidence. Many 
factors affect convergence and the rate a t which it is achieved which we consider 
in C hapter 6.
S tarting values are theoretically unim portant, as the chain will converge 
eventually regardless of its starting point (Raftery &; Lewis, 1992). However, 
using greatly over dispersed values will hinder convergence. The problem of 
possible illegal starting points has been mentioned above and is also dealt with 
in this chapter.
We are also concerned with the rate a t which proposals are accepted. High 
acceptance rates mean th a t the difference between existing and proposed values is 
too small and the chain moves slowly. Conversely, big jum ps are rarely accepted 
and the chain often does not move and may become stuck. This is discussed 
in Section 6.3. There are many recommendations of suitable acceptance rates 
to  be found in the literature varying between 15%-80%. In light of these we
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are satisfied with achieving acceptance rates of around 40%. Our proposals are 
generated using x ' = x  +  8, where x  is our existing value x ' is the proposed value 
and 5 ~  Af(0, a 2), this term  is modified for discrete variables to  be uniform over a 
particular range. The variance of S (or range) is inspected and may be modified 
to  ensure our results are satisfactory. Problems of ensuring positive values, where 
appropriate, are dealt with by use of a correction factor.
Of vital importance is actual convergence of the Markov Chains. Although 
acceptance rates may fall within the desirable range, they do not indicate 
convergence and this needs to be checked separately. The convergence techniques 
employed (see C hapter 6) in this project are those which are readily available via 
a public package - CODA (Best et a/., 1995). Although much work has been 
done in this area, we use them  purely as additional diagnostic tools since they 
are not wholly reliable. We noticed th a t the different diagnostics can give differing 
results as regards the recommended length of burn in, whether convergence has 
been achieved, and the run length required in order to produce reliable posterior 
estimates. These diagnostics can vary greatly depending on starting  points, 
especially over-dispersed starting values and the length of chain actually used to 
provide the estimates. Paradoxically, the required chain length recommended can 
increase substantially when using a longer chain to  calculate the recommended 
length. Often, the best and arguably most simple diagnostic tool to use is a 
visual check of the variable trace. No diagnostic can claim to be fool proof: we 
do not know if there is a small area of probability away from the main area which 
has yet to be visited, or, if visited, whether the chain spent the proportionately 
correct time in the respective area. This is where there is a valid argument for 
running several chains from different over-dispersed starting  points. The need for 
efficiency is also im portant, running several chains is wasteful as burn in periods 
are required for each, which are then discarded. Providing a chain has run for a 
sufficiently long time, we do need to  run more than  one chain.
These diagnostic checks provide a useful tool when combined with common sense 
bu t must not be relied on completely.
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9.2.4 R esults
The analyses produce a wealth of information which is presented to  the RUH in 
a  form at which enables informed decisions to  be made about potentially effective 
treatm ents. The results also build up a larger picture of the characteristics of 
the efficacy of different drugs with respect to tum our type. In Chapter 7 we 
present results from just a few patients and drugs in order to  illustrate a variety 
of responses.
As expected, there is considerable variation both within and between patients, 
drugs and tum our types. W hilst patients who respond well with one drug also 
tend to  respond well in others we cannot use outcome of one assay to predict 
another reliably. In the same way, a poor responder in some drugs may have 
good results from another. This dem onstrates the value of these assays in 
determining potentially efficacious treatm ents. Table 7.1 shows a summary of the 
main variables of interest. It demonstrates a huge difference between the LC90s 
(the x*) and also how the slope of the cell survival curves varies (b). W hilst 
there is some variation across drugs of the underlying rate of cells (A) this is not 
large; the between patient variation is large however, with solid clump tumours 
having the smallest values since cells clump together and it is the clumps which 
are counted not individual cells as this is impossible using current methods.
Different tum our types also affect the response to  the assay with solid clumps 
having the worst prognosis in nearly all of the drugs under investigation. 
Conversely, the CLL samples tend to  have the best responses. The main results 
of Table 7.1 are further subdivided into sample type as in Table 7.2.
The estim ated LC90s for patients vary in their accuracy and this will depend on 
several factors. If there is a very small control value, counts may be inaccurate 
and small differences in actual numbers of cells can make large differences in 
proportions. O ther factors to note include when the LC90 is not actually achieved 
within the drug range tested. In these cases there is very little information to 
use and results are not reliable. Efforts are made to rectify this and the ranges 
tested are reviewed and modified if this is a consistent problem. Also, missing 
d a ta  may cause problems and adversely affect accuracy.
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9.2.5 Future subjects
We also consider the problem of analysing additional assays w ithout the need to 
run the whole model with ju st one extra subject added per drug.
We use the posterior distributions of our main analysis to provide informative 
prior distributions for our secondary analysis.
The posterior distribution of the nodes of interest, (b, A, x*) were first checked for 
any correlation. Since this check offers no evidence otherwise, we shall consider 
them  as independent. Standard distributions were fitted and checked for fit: 
having shown satisfactory fits we are confident they are satisfactory for our 
purpose.
We use these fitted distributions as prior distributions for the new model. We 
obtain estim ated values for the LC90 which can be compared against those 
obtained from the main analysis showing the relative benefit or otherwise for 
this particular drug for the additional patient.
W hilst there is no need to rerun the main analysis for each extra patient if 
sufficient d a ta  for each drug and tum our sample combination have been collected 
to  obtain reliable posterior distributions, it would be a useful extra validity check 
to  compare these posterior distributions from both  the initial and subsequent 
analyses. We would expect them  to be similar unless the new d a ta  were drastically 
different from the original da ta  set.
9.2.6 M odel modification
The model we have described in C hapter 4 was chosen to mimic the data  
collection process as closely as possible. However, in light of recommendations 
subsequently made in Chapter 7 with regard to changing the system of cell 
counting and recording this data, modifications would be needed to  incorporate 
this new system. The cell survival proportions, the {yijk), had previously only 
been estim ated with varying degrees of accuracy, actual counts of the cells are 
now sometimes made in order to obtain exact values and provide more accurate
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data. This provides us directly with values for both nOij and riikj, the numbers 
of control and surviving cells respectively. The need for a categorical y^k value is 
then made redundant as we have an exact value for the proportion of surviving 
cells and not ju st a range within which to work.
To cope with this new counting system, if the riijk have been counted, there is 
now no need to  update this variable as it can now be treated as a d a ta  node rather 
than  a stochastic node. The model then would have to  be capable of coping with 
both  types of da ta  accordingly. Currently, only additional patients are counted 
in this way and their analysis is treated as distinct from the main body of data. 
If, however, this new data  were included in the main analysis, these modifications 
would need to  be incorporated.
9.2.7 Outliers
There is a paucity of literature dealing with the problems of outliers with respect 
to  Bayesian analyses. W hilst some authors concentrate on comparing the data  
with the prior distribution using Bayes factors (e.g. Young &; P e ttit, 1996) we 
are concerned with the fit of the posterior distribution and the actual data.
Our approach has focused on identifying possible outliers in two ways. The first 
involves looking a t the agreement or otherwise of the values recorded a t each dose 
across replicates. The second type of outlier comes from our assumption th a t the 
proportions of surviving cells decrease with increased dose; where an increase has 
been recorded we also investigate these values.
Having identified these suspect values they can be referred back to  the scientist 
who can double check th a t they are not transcription errors or possibly re-check 
the slides. If there is no obvious explanation for the apparent outlier we can see 
how it may affect the results.
We aim to assess the effect of these values by om itting them  and treating the 
results as missing and performing updates by accepting or rejecting new proposed 
values. The posterior distribution resulting from the MCMC analysis is then 
compared against the original recorded value. We can see from this comparison
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how often this value was visited and gauge how likely this value is under our 
model.
We see th a t on the whole, these outlying values have a only small effect on the 
overall results. The effect is magnified in the cases where there is little da ta  or a 
very small control value present. Otherwise, the simulation of these values tends 
to  give smaller posterior intervals as this estim ated value is pulled towards the 
existing ones.
A nother approach not implemented here could include the down weighting of 
suspect observations so their influence would be lessened. This would preclude 
being able to check the posterior distributions if the observations had been 
om itted and estim ated instead.
9.3 Further work
9.3.1 Outliers
The popularity of MCMC methods in recent years has generated a huge interest 
in the application of these methods. Much work has also been done on the vital 
questions of burn-in periods and convergence, see, for example Brooks &; Roberts 
(1999a, 1999b) or Cowles &: Carlin (1996).
However, although literature exists on the treatm ent of outliers, no formal 
m ethods have been derived to  check the fit of the resulting model as happens 
with, say, generalised linear models, where there are well defined procedures to 
follow.
Although part of our treatm ent of possible outlying values has been autom ated, 
the comparison of posterior distributions and the original observation have been 
performed manually. There is no procedure to  assess whether the discrepancy 
observed is of importance and thus it is necessarily subjective in this area.
It would be useful to  develop methods further along these lines so th a t suspect 
values could be objectively assessed for both  extremity and influence. In this way
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decisions are removed from the analyst and become less subject to  human error. 
Existing methods used to test probability models can be used as a basis on which 
to investigate further ways to analyse outliers. The main difference being tha t 
we are given a whole posterior distribution rather than  a single fitted value to 
compare against our initial value. Although we could use a sum m ary statistic 
such as the posterior mean this would ignore the vast m ajority of the available 
information.
This again indicates the importance of convergence as there is little point 
assessing outliers against a model which may not have converged.
9.3.2 M odel assumptions
Where we have made the model assumptions, there are often many options 
available to  us, for example different prior distributions or proposal distributions. 
We have used a simplistic distribution to represent the cell survival categories. 
A more sophisticated approach would allow any value to  fall within any category 
with some probability using a smoother distribution. This would allow more 
movement of the chain and negate the need for valid starting  values as all values 
are now allowed.
9.3.3 M odel extensions
W hilst it is beyond the scope of this thesis, it should be possible to  incorporate 
further d a ta  into the decision making process. Information on an individual 
patient may have some bearing on the effectiveness of a particular drug such as 
age, sex, stage of disease, previous treatm ent history etc. Additional information 
on the drugs such as potential side effects and possible interactions can also be 
included. A utility type function using as much da ta  as possible may be developed 
to further aid decision making about particular treatm ents.
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9.3.4 M odel Validation
At the moment, it is impossible to say with complete confidence how well our 
model performs w ithout further data. Since new counting techniques are now 
being implemented an additional check can also be made about the relative gain 
in the accuracy of our estimate.
9.4 Conclusions
We have developed the model used for analysis using as much information as 
possible in order to obtain estimates for param eters describing the dose response 
curves. O ut of the many options which are available to us in term s of methods 
used, the choice of prior probability distributions etc., we believe the final model 
gives a reliable mechanism with which to estim ate the LC90s and to  provide a 
basis for analysis of future subjects.
Although we are satisfied as to the convergence of the MCMC algorithm fitting 
the model, there are no foolproof convergence diagnostic methods and we need 
to  take great care in their application.
We use the posterior distributions obtained as new prior distributions for the new 
model derived to  analyse additional subjects. This gives us informative prior 
distributions for the secondary analysis and removes the need for hyper-prior 
distributions.
Outlying observations are only of concern when there is little other data, for 
example missing da ta  or small control values. Associated posterior intervals 
for the variables of interest in these cases are large reflecting their uncertainty. 
Little work has been done in this area and there is no formal methodology which 
currently exists. The literature does not deal with values departing from posterior 
distributions only from prior distributions. As, ideally, the posterior should be 
influenced little by the prior distribution and mostly by the data, this approach 
is not compatible with this project.
We have recommended a new more accurate way of assessing the actual
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proportions of surviving cells which requires counting all cells on a slide rather 
than guesstimating them. This could mean modifying the main model to 
incorporate both  types of da ta  available. However, this is more time consuming 
and not performed for every assay.
The results obtained from these analyses can be updated when there is sufficient 
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